N.C. te Grootenhuis, A.G.J. van der Zee, H.C. van Doorn, J. van der Velden, I. Vergote, V. Zanagnolo, P.J. Baldwin, K.N. Gaarenstroom, E.B. van Dorst, J.W. Trum, B.F.M. Slangen, I.B. Runnebaum, K. Tamussino, R.H. Hermans, D.M. Provencher, J.A. de Hullu, M.H.M. Oonk. Sentinel nodes in Vulvar Cancer: Long-term follow-up of the GROningen INternational Study on Sentinel nodes in Vulvar cancer (GROINSS-V) I.  Gynecol Oncol. 2016 Jan;140(1):8-14.

M. Astolfi, B. Peant, L. A. Muhammad, N. Rousset, J. Kendall-Dupont. Carmona, F. Monet, F. Saad, D. Provencher, A.-M. Mes-Masson and T. Gervais. Micro-dissected tumor tissues on chip: an ex vivo method for drug testing and personalized therapy. Accepté par Lab on a Chip, Royal Society of Chemistry. 19 octobre 2015.

Ledermann JA, Embleton AC, Raja F, Perren TJ, Jayson GC, Rustin GJ, Kaye SB, Hirte H, Eisenhauer E, Vaughan M, Friedlander M, González-Martín A, Stark D, Clark E, Farrelly L, Swart AM, Cook A, Kaplan RS, Parmar MK; ICON6 collaborators (Provencher,D). Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2016 Mar 12;387(10023):1066-74

Martin Köbel, Kurosh Rahimi, Peter Rambau, Chris Naugle, Cecile LePage, Leliane Meunier, Manon De Ladurantye, Sandra Lee, Samuel Leung, Ellen Goode, Susan S. Ramus, Joseph Carlson, Xiaodong Li, Carol A. Ewanowich, Linda E. Kelemen, Barabara Vanderhyden, Diane Provencher, David Huntsman, Cheng-Han Lee, C.Blake Gilks, Anne-Marie Mes Masson.  Immunohistochemical Algorithm for Ovarian Carcinoma Typing. Int J Gynecol Pathol. 2016 Mar 11. [Epub ahead of print].

Fujiwara K, Monk BJ, Lhommé C, Coleman RL, Brize A, Oaknin A, Ray-Coquard I, Fabbro M,Provencher D, Bamias A, Vergote I, DeCensi A, Zhang K, Vogl FD, Bach BA, Raspagliesi F. Health-related Quality of Life in Women With Recurrent Ovarian Cancer Receiving Paclitaxel Plus Trebananib or Placebo (TRINOVA-1). Ann Oncol. 2016 Jun;27(6):1006-13.

Charette Olivier, Bleau Gilles, El Haffaf Zaki, Richard Johanne, Rahimi Kurosh, Nolet Serge, Tonin Patricia, Mes-Masson Anne-Marie et Provencher Diane. Study of French-Canadian BRCA1-2 mutated ovarian cancer patients (FC-BMOC) with primary cytoreduction vs. neoadjuvant chemotherapy and interval cytoreduction for epithelial ovarian cancer (EOC). Current Oncology, Volume 23, number 3, June 2016.

Charette Olivier, Bleau Gilles, El Haffaf Zaki, Richard Johanne, Rahimi Kurosh, Nolet Serge, Tonin Patricia, Mes-Masson Anne-Marie et Provencher Diane. Relationship between genotype and clinical phenotype in French Canadian BRCA1-2 mutated women with ovarian cancer (FC-BMOC). Current Oncology, Volume 23, number 3, June 2016.

Madore Wendy-Julie, De Montigny Étienne, Benoujja Fouzi, Leduc Mikael, Godbout Nicolas, Boudoux Caroline, Mes-Masson Anne-Mrie, Rahimi Kurosh, Provencher Diane. Instrumentation dédiée à l’imagerie per-opératoire des trompes de Fallope. Current Oncology, Volume 23, number 3, June 2016.

Fleury H, Carmona E, Morin VG, Meunier L, Masson JY, Tonin PN, Provencher D, Mes-Masson AM. Cumulative defects in DNA repair pathways drive the PARP inhibitor response in high-grade serous epithelial ovarian cancer cell lines". Oncotarget. 2016 Jun 27.

Monk BJ, Poveda A, Vergote I, Raspagliesi F, Fujiwara K, Bae DS, Oaknin A, Ray-Coquard I, Provencher DM, Karlan BY, Lhommé C, Richardson G, Rincón DG, Coleman RL, Marth C, Brize A, Fabbro M, Redondo A, Bamias A, Ma H, Vogl FD, Bach BA, Oza AM. Final Results of a Phase 3 Study of Trebananib Plus Weekly Paclitaxel in Recurrent Ovarian Cancer (TRINOVA-1): Long-Term Survival, Impact of Ascites, and Progression-Free Survival-2. Gynecol Oncol. 2016 Oct;143(1):27-34

Pelletier MP, Trinh VQ, Stephenson P, Mes-Masson AM, Samouelian V, Provencher DM, Rahimi K.Microcystic, elongated and fragmented (MELF) pattern invasion is mainly associated with isolated tumor cell pattern metastases in FIGO grade I endometrioid endometrial cancer (EEC). Hum Pathol. 2017 Apr;62:33-39.

Mirza MR, Monk BJ, Herrstedt J, Oza AM, Mahner S, Redondo A, Fabbro M, Ledermann JA, Lorusso D, Vergote I, Ben-Baruch NE, Marth C, Mądry R, Christensen RD, Berek JS, Dørum A, Tinker AV, du Bois A, González-Martín A, Follana P, Benigno B, Rosenberg P, Gilbert L, Rimel BJ, Buscema J, Balser JP, Agarwal S, Matulonis UA; ENGOT-OV16/NOVA Investigators (Provencher DM). Efficacy of niraparib on progression-free survival (PFS) in patients (pts) with recurrent ovarian cancer (OC) with partial response (PR) to the last platinum-based chemotherapy. N Engl J Med. 2016 Dec 1;375(22):2154-216

Wendy-Julie Madore.  Wendy-Julie Madore ; Etienne De Montigny ; Andréanne Deschênes ; Fouzi Benboujja ; Mikael Leduc ; Anne-Marie Mes-Masson ; Diane Provencher ; Kurosh Rahimi ; Caroline Boudoux ; Nicolas Godbout  Morphologic 3D scanning of fallopian tubes to assist ovarian cancer diagnosis.  Proc. SPIE 9689, Photonic Therapeutics and Diagnostics XII, 96894D February 29, 2016.

Z. El Haffaf, N.Dumas, MC.Binet, F.Coron, B. Labraki, J. Richard, S.Nolet, D. Provencher M.Lefebvre, P. Hamet Pertinence d’une analyse multigène élargie dans l’évaluation génétique des cancers du sein et l’ovaire. Une réalité incontournable. 6e Symposium international sur le cancer héréditaire du sein et d el’ovaire.  BRCA : défis et opportunités. Montréal, 10-13 mai 2016.

Olivier Charette, Gilles Bleau, Zaki El Haffaf, Johanne Richard, Kurosh Rahimi, Serge Nolet, Patricia Tonin, Anne-Marie Mes-Masson, Diane Provencher. Study of French Canadian BRCA1/2–Mutated Ovarian Cancer Patients with Primary Cytoreduction for Epithelial Ovarian Cancer. 6e Symposium international sur le cancer héréditaire du sein et d el’ovaire.  BRCA : défis et opportunités. Montréal, 10-13 mai 2016.

Olivier Charette, Gilles Bleau,Zaki El Haffaf, Johanne Richard, Kurosh Rahimi, Serge Nolet, Patricia Tonin,|| Anne-Marie Mes-Masson, Diane Provencher. Relationship between Genotype and Clinical Phenotype in French Canadian BRCA1/2–Mutated Women with Ovarian Cancer. 6e Symposium international sur le cancer héréditaire du sein et de l’ovaire.  BRCA : défis et opportunités. Montréal, 10-13 mai 2016.

Wendy-Julie Madore, Etienne De Montigny, Fouzi Benboujja, Mikaël Leduc,Nicolas Godbout, Caroline Boudoux, Anne-Marie Mes-Masson, Kurosh Rahimi, Diane Provencher. Instrumentation dédiée à l’imagerie peropératoire des trompes de Fallope. 6e Symposium international sur le cancer héréditaire du sein et d el’ovaire.  BRCA : défis et opportunités. Montréal, 10-13 mai 2016.

Eman AlShehri, Suzanna L. Arcand, Kathleen Klein Oros, Anne-Marie Mes-Masson, Diane Provencher, Celia Greenwood, Patricia N. Tonin. Characterization of Genomic Landscapes of BRCA1- and BRCA2-Implicated Ovarian Cancers from French Canadian Women. 6e Symposium international sur le cancer héréditaire du sein et d el’ovaire.  BRCA : défis et opportunités. Montréal, 10-13 mai 2016.

Wejdan M. Alenezi, Suzanna L. Arcand, Dunarel Badescu, Timothee Revil, Anne-Marie Mes-Masson, Diane Provencher, Ioannis Ragoussis, Patricia N. Tonin. Investigation of Selected DNA Repair Genes in French Canadian Women with Ovarian Cancer Carrying BRCA1 or BRCA2 Mutations. 6e Symposium international sur le cancer héréditaire du sein et d el’ovaire.  BRCA : défis et opportunités. Montréal, 10-13 May 2016.June 2016

Suzanna L. Arcand, Frédéric Ancot, Dunarel Badescu, Timothée Revil, Claire S. Leblond, Alexandre Dionne-Laporte, Anne-Marie Mes-Masson, Diane Provencher, Guy Rouleau,  Ioannis Ragoussis, Patricia N. Tonin. A Targeted Analysis of Known and Emerging Cancer Susceptibility Genes in French Canadian Women with Breast Cancer Carrying BRCA1/BRCA2 Mutations. 6e Symposium international sur le cancer héréditaire du sein et d el’ovaire.  BRCA : défis et opportunités. Montréal, 10-13 mai 2016.

Alenezi ; Suzanna L. Arcand ; Dunarel Badescu ; Timothee Revil ; Anne-Marie Mes-Masson ; Diane Provencher ; Ioannis Ragoussis ; Patricia N. Tonin. Global analysis of whole exome sequencing data from BRCA1/ BRCA2 mutation carrier French Canadian women with ovarian cancer. 8th Canadian Conference on Ovarian Cancer Research, Niagara Falls Ontario, 14-17 mai 2016. Prix du jury!

Euridice Carmona ; Benjamin Péant ; Mélina Astolfi ; Abdul Lateef ; Jennifer Kendall-Dupont ; Liliane Meunier ; Diane Provencher ; Thomas Gervais ; Anne-Marie Mes-Masson. Micro-dissected ovarian tumors on-chip and protein biomarkers to predict carboplatin response of epithelial ovarian cancer. 8th Canadian Conference on Ovarian Cancer Research, Niagara Falls Ontario, 14-17 mai 2016.

Diane Provencher ; Olivier Charrette ; Gilles Bleau ; Zaki El Haffaf ; Kurosh Rahimi ; Serge Nolet ; Patricia Tonin. Relationship between genotype and clinical phenotype in French Canadian BRCA1-2 mutated women with ovarian cancer (FC-BMOC). 8th Canadian Conference on Ovarian Cancer Research, Niagara Falls Ontario, 14-17 mai 2016.

Diane Provencher, Olivier Charrette , Gilles Bleau , Zaki El Haffaf , Serge Nolet , Patricia Tonin , Anne-Marie Mes-Masson. Study of French-Canadian BRCA1-2 mutated ovarian cancer patients (FC-BMOC) with primary cytoreduction vs. neoadjuvant chemotherapy and interval cytoreduction for epithelial ovarian cancer (EOC). 8th Canadian Conference on Ovarian Cancer Research, Niagara Falls Ontario, May 14-17, 2016.

Cecile Le Page ; David Huntsman ; Diane Provencher ; Anne-Marie Mes-Masson. COEUR: A Pan-Canadian platform for the development of biomarker-driven subtype specific management of ovarian carcinoma. 8th Canadian Conference on Ovarian Cancer Research, Niagara Falls Ontario, 14-17 mai 2016.

Hubert Fleury ; Euridice Carmona ; Vincent G.Morin ; Liliane Meunier ; Jean-Yves Masson ; Patricia N.Tonin ; Diane Provencher ; Anne-Marie Mes-Masson. Synergistic effect of NER inhibitor and PARP inhibitor combination in resistant E. 8th Canadian Conference on Ovarian Cancer Research, Niagara Falls Ontario, 14-17 mai 2016. Prix du jury!

Llilians Calvo Gonzalez, Shuofei Cheng, Michael Skulimowski , Lise Portelance , Isabelle Clément , Diane Provencher, Anne-Marie Mes-Masson, and Francis Rodier. P16INK4A - associated cancer cell senescence is a major response to cytotoxic chemotherapy in high-grade serous ovarian cancer and predicts good clinical outcomes Llilians Calvo Gonzalez1*, Shuofei Cheng1*, Michael S. 8th Canadian Conference on Ovarian Cancer Research, Niagara Falls Ontario, 14-17 mai 2016.

Helen Mackay, Christopher J. Gallagher, Wendy R. Parulekar, Jonathan A. Ledermann, Deborah Kay Armstrong, Charlie Gourley, Ignacio Romero, Amanda Feeney, Paul Bessette, Marcia Hall, Johanne Ingrid Weberpals, Geoff Hall, Susie K Lau, Philippe Gauthier, Michael Fung-Kee-Fung, Elizabeth A. Eisenhauer, Chad Winch, Dongsheng Tu, Diane M. Provencher. OV21/PETROC: A randomized Gynecologic Cancer Intergroup (GCIG) phase II study of intraperitoneal (IP) vs. intravenous (IV) chemotherapy following neoadjuvant chemotherapy and optimal debulking surgery in epithelial ovarian cancer (EOC). 2016 ASCO Annual Meeting, 3-7 juin 2016.

Ursula A. Matulonis, Amit M. Oza, Angeles Alvarez Secord, Lynda D. Roman, Sarah Patricia Blagden, Susana N. Banerjee, J C Elkas, John J. Nemunaitis, Sharad A. Ghamande, Gini F. Fleming, Merry Jennifer Markham, Hal W. Hirte, Diane M. Provencher, Bristi Basu, Rebecca Sophie Kristeleit, Sue Naim, Yong Hao, Harold N. Keer, Mohammad Azab, Daniela Matei. Epigenetic resensitization to platinum in recurrent, platinum-resistant ovarian cancer (OC) using guadecitabine (SGI-110), a novel hypomethylating agent (HMA): Results of a randomized phase II study. 2016 ASCO Annual Meeting, 3-7 juin 2016.

Olivier Charette, Gilles Bleau, Zaki El Haffaf, Johanne Richard, Kurosh Rahimi, Serge Nolet, Patricia Tonin, Anne-Marie Mes-Masson, Diane Provencher. Study of French Canadian BRCA1/2–Mutated Ovarian Cancer Patients with Primary Cytoreduction for Epithelial Ovarian Cancer. Current Oncology, Vol. 23, No. 3, June 2016

Olivier Charette, Gilles Bleau,Zaki El Haffaf, Johanne Richard, Kurosh Rahimi, Serge Nolet, Patricia Tonin,|| Anne-Marie Mes-Masson, Diane Provencher. Relationship between Genotype and Clinical Phenotype in French Canadian BRCA1/2–Mutated Women with Ovarian Cancer . Current Oncology, Vol. 23, No. 3, June 2016

Wendy-Julie Madore, Etienne De Montigny, Fouzi Benboujja, Mikaël Leduc,Nicolas Godbout, Caroline Boudoux, Anne-Marie Mes-Masson, Kurosh Rahimi, Diane Provencher. Instrumentation dédiée à l’imagerie peropératoire des trompes de Fallope. Current Oncology, Vol. 23, No. 3, June 2016

Eman AlShehri, Suzanna L. Arcand, Kathleen Klein Oros, Anne-Marie Mes-Masson, Diane Provencher, Celia Greenwood, Patricia N. Tonin. Characterization of Genomic Landscapes of BRCA1- and BRCA2-Implicated Ovarian Cancers from French Canadian Women. Current Oncology, Vol. 23, No. 3, June 2016

Wejdan M. Alenezi, Suzanna L. Arcand, Dunarel Badescu, Timothee Revil, Anne-Marie Mes-Masson, Diane Provencher, Ioannis Ragoussis, Patricia N. Tonin. Investigation of Selected DNA Repair Genes in French Canadian Women with Ovarian Cancer Carrying BRCA1 or BRCA2 Mutations. Current Oncology, Vol. 23, No. 3, June 2016

Suzanna L. Arcand, Frédéric Ancot, Dunarel Badescu, Timothée Revil, Claire S. Leblond, Alexandre Dionne-Laporte, Anne-Marie Mes-Masson, Diane Provencher, Guy Rouleau,  Ioannis Ragoussis, Patricia N. Tonin. A Targeted Analysis of Known and Emerging Cancer Susceptibility Genes in French Canadian Women with Breast Cancer Carrying BRCA1/BRCA2 Mutations. Current Oncology, Vol. 23, No. 3, June 2016

Zaki El Haffaf, Nadine Dumas, Marie Claire Binet, Fanny Coron, Bouchra Labraki, Johanne Richard, Serge Nolet, Diane Provencher, Maude Lefebvre, Pavel Hamet. Pertinence d’une analyse multigène élargie dans l’évaluation génétique des cancers du sein et l’ovaire : une réalité incontournable. Current Oncology, Vol. 23, No. 3, June 2016

A. V. Tinker, H. Hirte, D Provencher, M Butler, D. Tu, H. Ritter, P Paralejas, SA. Hahn, N. Grenier, J. Ramsahai,L. Seymour. Dose Ranging Study of monalizumab (IPH220) in Patients with Gynecologic Malignancies: A trial of the Canadian Cancer Trials Group (CCTG): IND221. ENA 2016, Los Angeles 14-17 septembre, 2016.

B. Patra, E. Carmona, M.A. Lateef, J. Kendall-Dupont, B. Peant, D. Provencher, A.M. Mes-Masson et T. Gervais. Comparision of carboplatin sensitivities of 2D and microfluidic 3D cultures of ovarian cancer cell lines.  Conférence MicroTAS 2015, Dublin, Irelande, 9-13 octobre 2016

Lili Fu, MD, FRCPC; Huijun Wang, MD; Badia Issa-Chergui, MD, FRCPC; Diane Provencher, MD, FRCSC;   Zaki El Haffaf, MD;  Alex Ferenczy, MD, FRCPC. Synchronous mucinous neoplasia and metaplasia of the female genital tract in a patient with no typical clinical or molecular evidence of Peutz Jeghers syndrome: A case report with literature review. 16th Biennial Meeting of the IGCS 2016, LIsbonne, Portugal, 29-31 octobre 2016.

Helen Mackay, Christopher J. Gallagher, Wendy R. Parulekar, Jonathan A. Ledermann, Deborah Kay Armstrong, Charlie Gourley, Ignacio Romero, Amanda Feeney, Paul Bessette, Marcia Hall, Johanne Ingrid Weberpals, Geoff Hall, Susie K Lau, Philippe Gauthier, Michael Fung-Kee-Fung, Elizabeth A. Eisenhauer, Chad Winch, Dongsheng Tu, Diane M. Provencher. OV21/PETROC: A randomized Gynecologic Cancer Intergroup (GCIG) phase II study of intraperitoneal (IP) vs. intravenous (IV) chemotherapy following neoadjuvant chemotherapy and optimal debulking surgery in epithelial ovarian cancer (EOC). ASCO Annual Meeting, Chicago, June 3-7, 2016.

Tétreault-Laflamme A, Nguyen TV, Carrier JF, Samouëlian V, Sauthier Ph, Beauchemin MC, Barkati M. « Adjuvant Chemotherapy and Vaginal Vault Brachytherapy with or without Pelvic Radiotherapy for Stage 1 Papillary Serous or Clear Cell Endometrial Cancer » Int J Gynecol Cancer 2016;26: 301-306)

Bernardini MQ, Gien LT, Lau S, Altman AD, Gilks B, Ferguson SE, Köbel M, Samouëlian V, Wesa M, Cameron A, Nelson G, Han G, Clarke B, Ho TC, Panzarella T, Atenafu EG, McAlpine JN.«Treatment Related Outcomes in High-Risk Endometrial Carcinoma: Canadian High Risk Endometrial Cancer Consortium (CHREC) » Gynecol Oncol. 2016 Apr;141(1):148-54.

Samouëlian V, Leblanc E, Lhotellier V, Querleu D, Mechtouf N, Cardin GB, Revillion F and Rodier F. « Molecular detection of nodal involvement in uterine cervical cancer using cancer-specific biomarkers ». Oncotarget - Accepté avec corrections mineures

Rozenholc A, Dodge J, Bréguet M, Sauthier P. Gestational Trophoblastic Disease: Opportunities for a National Registry Collaboration. Int J Gynecol Cancer. 2016 Jul;26(6):1182-5.

du Bois A, Kristensen G, Ray-Coquard I, Reuss A, Pignata S, Colombo N, Denison U, Vergote I, Del Campo JM, Ottevanger P, Heubner M, Minarik T, Sevin E, de Gregorio N, Bidziński M, Pfisterer J, Malander S, Hilpert F, Mirza MR, Scambia G, Meier W, Nicoletto MO, Bjørge L, Lortholary A, Sailer MO, Merger M, Harter P; AGO Study Group led Gynecologic Cancer Intergroup/European Network of Gynaecologic Oncology Trials Groups Intergroup Consortium (et al Warkus T). Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncol. 2016 Jan;17(1):78-89.

Mousa A, Rahimi K, Warkus T. Neoadjuvant chemoradiotherapy followed by radical vulvectomy for adenoid cystic carcinoma of Bartholin's gland: a case report and review of the literature. Eur J Gynaecol Oncol. 2016;37(1):113-6.

Cormier B, Rozenholc AT, Gotlieb W, Plante M, Giede C, Communities of Practice (CoP) Group of the Society of Gynecologic Oncology of Canada (GOC). Sentinel lymph node procedure in endometrial cancer: A systematic review and proposal for standardization of future research. Gynecol Oncol. 2015 Jun 3.

Cormier B, Gotlieb W, Dawson L. Sentinel Lymph node (SLN) mapping in endometrial and cervical cancer. The Society of Gynecologic Oncology of Canada (GOC), position statement July 2017 (publié également en version française: Identification du ganglion sentinelle dans le contexte du cancer de l’endomètre et du col de l‘utérus.). GOC position statement available on the GOC Corporate website. Août 2017.

Rajih E, Tholomier C, Cormier B, Samouëlian V, Warkus T, Liberman M, Widmer H, Lattouf JB, Alenizi AM, Meskawi M, Valdivieso R, Hueber PA, Karakewicz PI, El-Hakim A, Zorn KC. Error reporting from the da Vinci surgical system in robotic surgery: A Canadian multispecialty experience at a single academic centre. Can Urol Assoc J. 2017 May;11(5):E197-E202

Moria H. Belanger, Lena Dolman, Suzanna L. Arcand, Zhen Shen, George Chong, Anne-Marie Mes-Masson, Diane Provencher, and Patricia N. Tonin. A targeted analysis identifies a high frequency of BRCA1 and BRCA2 mutation carriers in ovarian cancer cases from a founder population (CGE-00465-2014).  J Ovarian Res. 2015 Mar 27;8(1):1

Corkery DP, Le Page C, Meunier L, Provencher D, Mes-Masson AM, Dellaire G. PRP4K is a HER2-regulated modifier of taxane sensitivity.  Cell Cycle. 2015 Apr 3;14(7):1059-69.

Karen Gambaro, Michael CJ Quinn, Katia Y Cáceres-Gorriti, Rebecca S Shapiro, Diane Provencher, Kurosh Rahimi, Anne-Marie Mes-Masson and Patricia N Tonin. Low levels of IGFBP7 expression in high-grade serous ovarian carcinoma is associated with patient outcome BMC Cancer. 2015 Mar 17;15:135

Suzanna L. Arcand, Mohammed R. Akbari, Anne-Marie Mes-Masson, Diane Provencher, William D. Foulkes, Steven A. Narod, and Patricia N. Tonin . Germline TP53 mutational spectrum in French Canadians with breast cancer. BMC Med Genet. 2015 Apr 12;16:24.

Patricia Pautier, Soslow, D M Provencher, G Mangili, A Hamilton, N Siddiqui, AW Westermann, P Harter, Eun Ji Nam, Ray-Coquard I. GCIG consensus review for high grade undifferentiated sarcoma. Accepted by International Journal of Gynecologic Cancer. January 2015.

Castellsagué E, Liu J, Volenik A, Giroux S, Gagné R, Maranda B, Roussel-Jobin A, Latreille J, Laframboise R, Palma L, Kasprzak L, Marcus VA, Breguet M, Nolet S, El-Haffaf Z, Australie K, Gologan A, Aleynikova O, Oros-Klein K, Greenwood C, Mes-Masson AM, Provencher D, Tischkowitz M, Chong G, Rousseau F, Foulkes WD. Characterization of a novel founder <i>MSH6</i> mutation causing Lynch syndrome in the French Canadian population" (CGE-00654-2014.R1). Clin Genet. 2015 Jun;87(6):536-42.

Berdugo J, Gauthier P, Provencher D, Matte C, Piché J, Rahimi K.Spindle cell epithelioma of the vagina: report of two cases, literature review and new immunohistochemical markers. Int J Surg Pathol. 2015 May 20

Ancot Frédéric, Arcand Suzanna L., Mes-Masson Anne-Marie, Provencher Diane M., Tonin Patricia N.. Double PALB2 and BRCA1/BRCA2 mutation carriers are rare in breast cancer and breast-ovarian cancer syndrome families from the French Canadian founder population.  Oncol Lett. 2015 Jun;9(6):2787-2790.

Castellsagué E, Liu J, Volenik A, Giroux S, Gagné R, Maranda B, Roussel-Jobin A, Latreille J, Laframboise R, Palma L, Kasprzak L, Marcus VA, Breguet M, Nolet S, El-Haffaf Z, Australie K, Gologan A, Aleynikova O, Oros-Klein K, Greenwood C, Mes-Masson AM, Provencher D, Tischkowitz M, Chong G, Rousseau F, Foulkes WD. Characterization of a novel founder MSH6 mutation causing Lynch syndrome in the French Canadian population. Clin Genet. 2015 Jun;87(6):536-42.

Chene G, Ouellet V, Rahimi K, Barres V, Meunier L, De Ladurantaye M, Provencher D, Mes Masson AM. DNA damage signaling and apoptosis in preinvasive tubal lesions of ovarian carcinoma..  Int J Gynecol Cancer. 2015 Jun;25(5):761-9

Chene G, Ouellet V, Rahimi K, Barres V, Provencher D, Mes Masson AM. The ARID1A pathway in ovarian clear cell and endometrioid carcinoma, in contiguous endometriosis and in benign endometriosis. Int J Gynaecol Obstet. 2015 Jul;130(1):27-30

Gautier Chene, Vernique Ouellet, Kurosh Rahimi, Veronique Barres, Liliane Meunier, Manon De laduranteye, Diane M. Provencher and Anne Marie Mes-Masson. Expression of stem cell markers in preinvasive tubal lesions of ovarian carcinoma. Biomed Res Int. 2015.

Sandra Lee, Anna Piskorz, Cécile Le Page, Anne-Marie Mes Masson, Diane Provencher, David Huntsman, Wenqian Chen, Paul E. Swanson, C. Blake Gilks, Martin Köbel. Calibration and optimization of p53, WT1, and Napsin A immunohistochemistry ancillary tests for histotyping of ovarian carcinoma: Canadian Immunohistochemistry Quality Control (CIQC) experience. Accepté par le journal IJGP le 26 août 2015.

Hubert Fleury, Laudine Communal, Euridice Carmona, Lise Portelance, Suzanna L. Arcand, Kurosh Rahimi, Patricia N. Tonin, Diane Provencher, Anne-Marie Mes-Masson. Novel high-grade serous epithelial ovarian cancer cell lines that reflect the molecular diversity of both the sporadic and hereditary disease. Genes & Cancer, Vol.6 (9-10), septembre 2015.

Martin Turcotte, Kathleen Spring, Sandra Pommey, Guillaume Chouinard, Isabelle Cousineau,  Joshy Gorges, Gregory M. Chen, Deena M.A. Gendoo, Benjamin Haibe-Kains, Thomas Karn7, Kurosh Rahimi , Cécile Lepage, Diane Provencher, Anne-Marie Mes-Masson, John Stagg. CD73 is associated with poor prognosis in high-grade serous ovarian cancer. Accepté par le journal Cancer Research, septembre 2015

Maud Marques, Marie-Claude Beauchamp, Hubert Fleury, Ido Laskov, Sun Qiang, Manuela Pelmus, Diane Provencher, Anne-Marie Mes-Massons, Walter Gotlieb and Michael Witcher. Chemotherapy reduces PARP1 in cancers of the ovary:  implications for future clinical trials involving PARP inhibitors. BMC Medicine 2015 Sep 9;13:217

Feriel Boumedian, Jean-Philippe Adam, Diane Provencher M.D., Nathalie Letarte, Khalid Akkour2 M.D. Single agent trabectedin in heavily pretreated patients with recurrent ovarian cancer (ROC). Présenté au GOC’s 36th AGM Scientific Program. Janvier 2015

Amit Oza, Ignace Vergote, Lucy Gilbert, Prafull Ghatage, Alla Lisyankaya, Sharad Ghamande, Setsuko Chambers, Jose Angel Arranz, Diane Provencher, Paul Bessette, Ursula Matulonis, Ronie Shapira-Frommer, Amnon Amit, Romnee Clark, James T. Symanowski, Richard Penson, R. Wendell Naumann. A Randomized Double-Blind Phase 3 Trial Comparing Vintafolide (EC145) and Pegylated Liposomal Doxorubicin (PLD/Doxil®/Caelyx®) in Combination Versus PLD in Participants With Platinum-Resistant Ovarian Cancer (PROCEED) (NCT01170650), Présenté au Society of Gynceologic Oncologists Annual Meeting, Chicago,  28-31 mars 2015

N. Hadj Bekkouche, Z. El Haffaf, D. M. Provencher.  Devrions-nous nous préoccuper des hommes porteurs de mutations dans les gènes BRCA 1 et 2 ? Présenté à la journée annuelle de la recherche du département d’obstétrique- gynécologie de l’Université de Montréal. 24 avril 2015.

Feriel Boumedien, Jean-Philippe Adam, BCPS, Khalid Akkour, Nathalie Letarte, Diane Provencher. Single agent Trabectedin in heavily pretreated patients with recurrent ovarian cancer (ROC). Présenté à l’ ASCO 2015. Chicago, 29 mai au 2 juin 2015.

Bradley J. Monk, Andrés Poveda, Ignace Vergote, Francesco Raspagliesi, Keiichi Fujiwara, Duk-Soo Bae, Ana Oaknin, Isabelle Ray-Coquard, Diane M. Provencher, Beth Y. Karlan, Catherine Lhommé, Gary Richardson, Dolores Gallardo Rincón, Robert L. Coleman, Arija Brize, Kathy Zhang, Florian D. Vogl, Bruce A. Bach, Amit M. Oza. Impact of trebananib plus weekly paclitaxel on overall survival (OS) in patients (pts) with recurrent ovarian cancer and ascites: results from the phase 3 TRINOVA-1 study. Présenté à l’ ASCO 2015. Chicago, 29 mai au 2 juin 2015.

Amit Oza, Johanne Weberpals, Diane Provencher, Eva-Maria Grischke, Marcia Hall, Denise Uyar, Maria Diz, Frederik Marme, Alexey Kuzmin, Per Rosenberg, Robert Wenham, Jingjun Qiu, Mark Anthony Lee, Ji Liu, Shelonitda Rose, Kathleen Moore .  An international biomarker-directed randomized Phase II trial of AZD1775 plus paclitaxel and carboplatin for the treatment of women with platinum-sensitive, TP53-mutant ovarian cancer. Présenté à l’ ASCO 2015. Chicago, 29 mai au 2 juin 2015.

Janet Dancey, Monika K. Krzyzanowska, Diane Provencher, Winson Cheung, Robyn J. Macfarlane, Thierry Alcindor, Prafull Ghatage, Abha Gupta, Michael Sawyer, Stephen Welch, Muhammad Salim, Scott Laurie, Susan Ellard, Donna Wall, Joana Sederias, Torsten Nielsen, Sylvia Asa, John McPherson, Ming Tsao, Hal Hirte. NCIC CTG IND.206: a phase II umbrella trial of sunitinib (S) or temsirolimus (T) in advanced rare cancers. Présenté à l’ASCO 2015. Chicago, 29 mai au 2 juin 2015.

Patricia N. Tonin, Karine Bédard, Suzanna L. Arcand, Dunarel Badescu, Timothee Revil, Eman AlShehri,, Claire Lebland, Alexandre Diaonne-Laporte, Anne-Marie Mes-Masson, William Foulkes, Zaki El Haffaf, Edenir Palmero, Diane Provencher, Jean-Yves Masson. A new candidate ovarian cancer susceptibility gene identified in French Canadian women with ovarian cancer. Accepté pour presentation à The Canadian Cancer Research Conference, 8-10 Novembre 2015

K. Ochiai, A. Okamoto, G. Stuart, N. Yanihara, D. Aoki, M. Bacon, M. Bookman, K. Fujiwara, A. Gonzales, P. Harter, J. W. Kim, J. Ledermann, El Pudjade-Lauraine and M. Quinn, on behalf of the participants of the 5th Ovarian Cancer Consensus Conference including Diane Provencher. 2015 Gynecologic Cancer InterGroup Consensus Statement on Clinical Trials in Ovarian Cancer: Reports from the 5th Ovarian Cancer Consensus Conference. Japon, novembre 2015.

M.K. Wilson, El Pujade-Lauraine, D. Aoiki, M. R. Mirza, D. Lorusso, A.M. Oza, A. du Bois, I. Vergote, A. Reuss, M. Bacon, M. Friedlander, D. Rincon, F. Joly, S.-J. Chang, A.M. Ferrero, J. Edmondson, P. Wimberger, J. Maenpaa, D. Gaffney, R. Zhang, A. Okamoto, G. Stuart, and K. Ochiai, on behalf of the participants of the 5th Ovarian Cancer Consensus Conference including Diane Provencher. 5th Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: Recurrent Disease. Japon, novembre 2015.

A.F.Leary, M. Quinn, K. Fujiwara, R. Coleman, E. Kohn, T. Sugiyama, R. Glasspool, I. Ray-Coquard, N. Colombo, M. Bacon, A. Zeimet, A. Westermann, E. Gomez-Garcia, D. Provencher, S. Welch, W. Small, D. Millan, A. Okamoto, G. Stuart, K. Ochiai and on behalf of the participants of the 5th Ovarian Cancer Consensus Conference including Diane Provencher.  5th Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup (GCIG): Clinical trail design for rare ovarian tumours. Japon, novembre 2015.

A. Karam, J.A. Ledermann, J-W. Kim, J, Sehouli, K. Lu, C. Gourley, N. Katsumat, R. A. Burger, B-H. Nam, M. Bacon, C. Ng, J. Pfisterer, R.L.M. Bekkers, A. Casado Herraez, A. Redondo, H. Fujiwara, N. Gleeson, O. Rosengarten, G. Scambia, J. Zhu, A. Okamoto, G. Stuart, K. Ochiai and on behalf of the participants of the 5th Ovarian Cancer Consensus Conference including Diane Provencher. 5th Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: First Line Interventions. Japon, novembre 2015.

J. McGee, M. Bookman, P. Harter, C. Marth, I. McNeish, K. N. Moore, A. Poveda, F. Hilpert, K. Hasegawa, M. Bacon, C. Gatsonis, A. Brand, F. Kridelka, J. Berek, P.B. (N.) Ottevanger, T. Levy, S. Silverberg, B. –G. Kim, H. Hirte, A. Okamoto, G. Stuart, K. Ochiai and on behalf of the participants of the 5th Ovarian Cancer Consensus Conference including Diane Provencher. 5th Ovarian Cancer Consensus Conference: individualized Therapy and patient Factors. Japon, novembre 2015.

N.C. Te Grootenhuis, A.G.J. Van der Zee, H.C. Van Doorn, J. Van der Velden, I. Vergote, V. Zanagnolo, P.J. Baldwin, K.N. Gaarenstroom, E.B. Van Dorst, J.W. Trum, B.F.M. Slangen, I.B. Runnebaum, K. Tamussino, R.H. Hermans, D.M. Provencher, J.A. De Hullu, M.H.M. Oonk. Sentinel nodes and Vulvar cancer:  Long-term follow-up of the GROningen INternational Study on Sentinel nodes in Vulvar cancer (GROINSS-V-I). ESGO 2015.

Berdugo J, Gauthier P, Provencher D, Matte C, Piché J, Rahimi K. Spindle Cell Epithelioma of the Vagina: Report of Two Cases, Literature Review, and New Immunohistochemical Markers. Int J Surg Pathol. 2015 May 2015

Guilbert MC, Samouëlian, V, Rahimi K, « Uterine leiomyoma with osteoclast-like giant cells. »  Int J Gynecol Pathol. 2015 Jul 9.

Kiely DJ, Gotlieb WH, Lau S, Zeng X, Samouelian V, Ramankumar AV, Zakrzewski H, Brin S, Fraser SA, Korsieporn P, Drudi L, Press JZ. « Virtual-reality robotic surgery simulation curriculum to teach robotic suturing: a randomized controlled trial. » J Robotic Surgery. 2015 May. DOI 10.1007/s11701-015-0513-4

Altman A, Ferguson SE, Atenafu EG, Kobel M, McAlpine JN, Panzarella T, Clarke B, Lau S, Gien LT, Gilks B, Cameron A, Nelson G, Han G, Samouelian V, Ho TC, Louie K, Bernardini MQ « Canadian High Risk Endometrial Cancer (CHREC) Consortium: Analyzing the Clinical Behaviour of High Risk Endometrial Cancers » Gynecol Oncol. 2015 Nov;139(2):268-74.

Sauthier P, Breguet M, Rozenholc A, Sauthier M. Quebec Trophoblastic Disease Registry: How to Make an Easy-To-Use Dynamic Database. Int J Gynecol Cancer. 2015 May;25(4):729-33

Beatrice Cormier MD, Joyce Barlin MD, Olivier Charette, Lei Kou MS, Changhong Yu MS, Michael W Kattan PhD, Dennis S. Chi MD and Diane Michele Provencher MD. External validation of an all-stage ovarian cancer nomogram: Is BRCA status more predictive than family history? Présenté au 45th Annual Meeting of Women’s Cancer de la Society of Gynecologic Oncology. Tampa, Florida, US, 24-25 Mars 2014

Cáceres-Gorriti KY, Carmona E, Barrès V, Rahimi K, Létourneau IJ, Tonin PN, Provencher D, Mes-Masson AM. RAN Nucleo-Cytoplasmic Transport and Mitotic Spindle Assembly Partners XPO7 and TPX2 Are New Prognostic Biomarkers in Serous Epithelial Ovarian Cancer. PLoS One. 2014 Mar 13;9(3)

Chene G, Ouellet V, Rahimi K , Barres V, Caceres K, Meunier L, Cyr L, De Ladurantaye M, Provencher D, Mes Masson AM. DNA damage signalling and apoptosis in preinvasive tubal lesions of ovarian carcinoma. Int J Gynecol Cancer. 2014 Jul 1.

Bradley J. Monk, Andrés Poveda, Ignace Vergote, Francesco Raspagliesi, Keiichi Fujiwara, Duk-Soo Bae, Ana Oaknin, Isabelle Ray-Coquard, Diane M. Provencher, Beth Y. Karlan, Catherine Lhommé, Gary Richardson, Dolores Gallardo Rincón, Robert L. Coleman, Thomas J. Herzog, Christian Marth, Arija Brize, Michel Fabbro, Andrés Redondo, Aristotelis Bamias,0 Marjan Tassoudji, Lynn Navale, Douglas J. Warner, and Amit M. Oza. Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial. The Lancet Oncology: 15(8); 799-808, juillet 2014.

Philipp Harter, MD, David Gershenson, MD, PhD, Catherine Lhomme, MD, PhD, Fabrice Lecuru, MD, PhD, Jonathan Ledermann, MD, FRCP, Diane M. Provencher, MD, PhD, Delia Mezzanzanica, MD, PhD, Michael Quinn, MD, PhD, Johanna Maenpaa, MD, PhD, Weon Kim, MD, PhD, Sven Mahner, MD, PhD, Felix Hilpert, MD, PhD, Klaus Baumann, MD, Jacobus Pfisterer, MD, PhD, and Andreas du Bois, MD, PhD Gynecologic Cancer InterGroup (GCIG) Consensus Review for Ovarian Tumors of Low Malignant Potential (Borderline Ovarian Tumors) Int J Gynecol Cancer, 2014;24(S3):S5-S8

Charlie Gourley & David Gershenson, Farley, D M Provencher, S Pignata, L Mileshkin,  P Harter,  J Maenpaa, Jae-Weon Kim, E Pujade Lauraine, R Glasspool, I Ray-Coquard. GCIG consensus review for ovarian and primary peritoneal low grade serous carcinomas. Int J Gynecol Cancer:24(S3);S9-S13, novembre 2014

Nick Reed, Glasgow, UK, and Patricia Pautier, IGR, Villejuif, France, Soslow, A Fyles, D M Provencher,  G Kichenadasse, A du Bois,  E Åvall-Lundqvist, Cheol Hun Choi, I Ray-Coquard. GCIG consensus review for small cell carcinoma of the ovary. Int J Gynecol Cancer:24(S3);S30-S34, novembre 2014

Ray-Coquard I, Brown J, Harter P, Provencher DM, Fong P, Maenpaa J, Ledermann J, Emons G, Berton-Rigaud D, Glasspool R, Bryce J, Colombo N. GCIG consensus review for ovarian Sex cord Stromal Tumors (SCSTs).  Int J Gynecol Cancer:24(S3);S42-S47, novembre 2014

Patricia Pautier, Eun Ji Nam,  Diane M. Provencher, Anne L. Hamilton, Giorgia Mangili, Nadeem Ahmad Siddiqui, Anneke M. Westermann, Nicholas Simon Reed, Philipp Harter, Isabelle Ray-Coquard. Gynecologic Cancer InterGroup (GCIG) Consensus Review for High-Grade Undifferentiated Sarcomas of the Uterus. Int J Gynecol Cancer 2014;24(S3): S73-S77, novembre 2014

Satoru Sagae, Nobuyuki Susumu, Akila N. Viswanathan, Daisuke Aoki, Backes, D M Provencher, M Vaughan , CL Creutzberg, C Kurzeder, G Kristensen, Chulmin Lee, JE Kurtz, R Glasspool, W Small. GCIG consensus review for uterine serous carcinoma. Int J Gynecol Cancer 2014;24(S3): S83-S89, novembre 2014

Toyomi Satoh, Yuji Takei, Isabelle Treilleux, Mojgan Devouassoux-Shisheboran, Jonathan Ledermann, Akila N. Viswanathan, Sven Mahner, Diane M. Provencher, Linda Mileshkin, Elizabeth A˚vall-Lundqvist, Patricia Pautier, Nicholas Simon Reed, and Keiichi Fujiwara. Gynecologic Cancer InterGroup (GCIG) Consensus Review for Small Cell Carcinoma of the Cervix. Int J Gynecol Cancer 2014;24(S3): S102-S108, novembre 2014

Andrea R. Spence, PhD, Abdulaziz Alobaid, M.D., Pierre Drouin, M.D., Patricia Goggin, M.D., Lucy Gilbert, M.D., Diane Provencher, M.D., Pierre Tousignant, M.D., PhD, James Hanley, PhD, Eduardo L. Franco, DrPH.  Screening Histories and Contact with Physicians as Correlates of Cervical Cancer Risk in Montreal, Canada. Current Oncology, Décembre 2014.

Binet Marie-Claire, Dumas Nadine, Szuto Anna, Lefebvre Maude, Nolet Serge, Provencher Diane, Richard-Chesney Johanne, Hamet Pavel, El Haffaf Zaki. Should We Do More and Expand the Indications of Genetic Testing for Patients With Breast and/or Ovarian Cancer and Their Families. 5th International Symposium on hereditary breast and ovarian cancer, Montréal, 23-25 avril 2014.

Karine Bédard, Suzanna L. Arcand, Najmeh Alirezaie, Jacek Majewski, Serge Nolet, Zaki El Haffaf , Diane M. Provencher , Anne-Marie Mes-Masson, Patricia N. Tonin Exome Sequencing of a Rare Ovarian Cancer Family Found Negative For BRCA1 and BRCA2 Mutations. RMGA, Montréal, 14-16 mai 2014

D M Provencher and H. Mackay, D. Tu, D. Armstrong, J. Ledermann, C. Gallagher and E. Eisenhauer. NCIC CTG OV.21 a phase II/III trial:  Feasibility and Safety Results of the Phase II component. CCOCR 2014, Victoria, Colombie-Britannique, 25-27 mai 2014.

Chene G, Ouellet V, Rahimi K , Barres V, Caceres K, Meunier L, Cyr L, De Ladurantaye M, Provencher D, Mes Masson AM. DNA Damage Signaling and Apoptosis in Preinvasive Tubal Lesions of High-Grade Serous Ovarian Carcinoma. CCOCR 2014, Victoria, Colombie-Britannique, 25-27 mai 2014.

Mélina Astolfi, Benjamin Péant, Jennifer Kendall-Dupont3,4, Abdul Lateef, Olivier Morin, Sina Fartoumi, Diane Provencher, Anne-Marie Mes-Masson, and Thomas Gervais Miniaturization of tumor samples and incubation devices multiplies possibilities for direct drug testing. CCOCR 2014, Victoria, Colombie-Britannique, 25-27 mai 2014.

Martin Köbel, Christopher Naugler, Kurosh Rahimi, Cécile Le Page, Liliane Meunier, Manon De Ladurantaye, Barbara Vanderhyden, Diane Provencher, David G. Huntsman, Anne-Marie Mes-Masson. Immunohistochemical algorithm for ovarian carcinoma typing. CCOCR 2014, Victoria, Colombie-Britannique, 25-27 mai 2014.

Moria H. Belanger, Lena Dolman, Suzanna L. Arcand, Zhen Shen, George Chong; Anne-Marie Mes-Masson, Diane Provencher, Patricia N. Tonin.  A targeted analysis identifies a high frequency of BRCA1 and BRCA2 mutation carriers in ovarian cancer cases from a founder population. CCOCR 2014, Victoria, Colombie-Britannique, 25-27 mai 2014.

Fosaprepitant as salvage treatment of chemotherapy-induced vomiting (CIV) in breast and gynecological cancer, Présentation orale au MASCC/ISOO Symposium 2014.  Miami, USA, 26-28 juin 2014.

Phillip H. Kuo, Diane Provencher, James Symanowski, Binh Nguyen, Taylor Benson, Amit M. Oza. Interreader variability of assessment of 99mTc-etarfolatide scans in evaluating tumor folate receptor (FR) status for selection of patients for FR-targeted therapy. WMIC 2014, Séoul, Corée, 17-20 septembre 2014.

G. Chen1, V. Ouellet, K. Rahimi, V. Barres, K. Caceres, L. Meunier, L. Cyr, M. De Ladurantaye, D. Provencher, A.M. Mes Masson.DNA damage signaling and apoptosis in preinvasive tubal lesions of ovarian carcinoma. Présenté au 15th biennial meeting of the International Gynecologic Cancer Society (IGCS). Melbourne, Australie, 8-11 novembre 2014.

G. Chene, V. ouellet, K. Rahimi, V. Barres, K. Caceres, L. Meunier, L. Cyr, M. De Ladurantaye, D. Provencher, A.M. Mes Masson The Arid 1A pathway in ovarian clear cell and endometrioid carcinoma, in continguous endometriosis and in benign endometriosis.  Présenté au 15th biennial meeting of the International Gynecologic Cancer Society (IGCS). Melbourne, Australie, 8-11 novembre 2014.

Balsat C, Signolle N, Goffin F, Delbecque K, Plancoulaine B, Sauthier P, Samouëlian V, Béliard A, Munaut C, Foidart JM, Blacher S, Noël A, Kridelka F. « Computer-assisted analysis of the global lymphatic network in human cervical tissues. » Mod Pathol. 2014 Jun;27(6):887-98

Marie-Hélène Mayrand, Helen Trotter, Francois Coutlée, James Bentley, Laurie Elit, Thomas Ehlen, Susie Lau, Brian Hauck, Marie Plante, Betsy Brydon, Philippe Sauthier, Joan Murphy, Patricia Fisch, Paul Bessette and Patricia Power "The COHIPP TrialL (Colposcopy vs. HPV Testing to Identify Persistent Cervical Pre-Cancers Post Treatment): Results at Recruitment and Randomization”. Conference IPV 2014, soumis le 15 mars 2014.

Rozenholc A, Breguet M, Sauthier Ph. GOC Tropho Survey: Soon a Canadian Trophoblastic Disease Registry?. The GOC News – Spring 2014.

Breguet Magali, Sauthier Philippe.  How we manage trophoblastic diseases and what about a trophoblastic diseases’ registry? A GOC members’ survey.  Journal of Obstetrics and Gynaecology Canada, Vol.35: no.5, Mai 2014.

Balsat C, Signolle N, Goffin F, Delbecque K, Plancoulaine B, Sauthier P, Samouëlian V, Béliard A, Munaut C, Foidart JM, Blacher S, Noël A, Kridelka F. Improved computer-assisted analysis of the global lymphatic network in human cervical tissues.  Mod Pathol. 2014 Jun;27(6):887-98

Pina Annick, Sauthier Philippe, Rahimi Kurosh. Vulvar Trichoblastoma : Case Report and Literature Review. © American Society for Colposcopy and Cervical Pathology, 2014. J Low Genit Tract Dis. 2014 Jan 28

Fawaz ZS, Barkati M, Beauchemin MC, Sauthier P, Gauthier P, Nguyen TV.Cervical necrosis after chemoradiation for cervical cancer: case series and literature review. Radiat Oncol. 2013 Sep 23;8(1):220.

Tamal Das, Liliane Meunier, Laurent Barbe, Diane Provencher, Olivier Guenat, Thomas Gervais, and Anne-Marie Mes-Masson Empirical Chemosensitivity Testing in a Spheroid Model of Ovarian Cancer using a Microfluidics-based Multiplex Platform. Biomicrofluidics, vol.7 (1), Jan.2013

Karen Gambaro, Michael C. J. Quinn, Paulina Wojnarowicz, Suzanna L. Arcand, Manon de Ladurantaye, Zhen Shen, Veronique Barres, Jean-Sébastien Ripeau, Ann M. Killary, Elaine C.Davis, Josée Lavoie, Diane M. Provencher, Anne-Marie Mes-Masson, Mario Chevrette and Patricia N. Tonin. VGLL3 expression is associated with a tumour suppressor phenotype in epithelial ovarian cancer. Molecular Oncology 16 janvier 2013..

Cécile Le Page, Martin Köbel, Manon de Ladurantaye, Kurosh Rahimi, Jason Madore, Sindy Babinszky, Dimcho R. Bachvarov, Magdalena Bachvarova, Marie-Claude Beauchamp, Carol E Cass, Dianne Chadwick, Crane Colleen, Sambasivarao Damaraju, Jennifer Dufour, Walter H. Gotlieb, Steve E. Kalloger, Lise Portelance, Jessica N. McAlpine, Isabelle Matte, Alain Piché, Patricia Shaw, Barbara C. Vanderhyden, Peter H. Watson, David G. Huntsman, Diane M. Provencher, Anne-Marie Mes-Masson. Specimen quality evaluation from Canadian Biobanks participating in the COEUR repository. Running title: Quality control of an ovarian cancer tissue repository. Acceptée par Biopreservation and Biobanking, janvier 2013.

Chene G, Rahimi K, Mes-Masson AM, Provencher D. Surgical Implications of the Potential New Tubal Pathway for Ovarian Carcinogenesis. J Minim Invasive Gynecol. 2013 Jan 15. Marc Tischkowitz, Nelly Sabbaghian, Nancy Hamel, Carly Pouchet, William D. Foulkes, Anne-Marie Mes-Masson, Diane M. Provencher , Patricia N. Tonin. Contribution of the PALB2 c.2323C>T [p. Q775X] founder mutation in well-defined breast and/or ovarian cancer families and unselected ovarian cancer cases of French Canadian descent. BMC Med Genet. 2013 Jan 9;14:5.

Chene G, Penault-Llorca F, Robin N, Cayre A, Provencher DM, Dauplat J. Early detection of ovarian cancer: Tomorrow? A review. J Gynecol Obstet Biol Reprod (Paris). 2013 Feb;42(1)5-11.

MCJ Quinn*, PM Wojnarowicz*, A Pickett, DM Provencher, A-M Mes-Masson, PN Tonin. FKBP10/FKBP65 expression in high-grade ovarian serous carcinoma and its association with patient outcome. Int J Oncol. 2013 Mar;42(3):912-20

Oros KK, Arcand SL, Bayani J, Squire JA, Mes-Masson AM, Tonin PN, Greenwood CM, et al. (Provencher, D). Analysis of Genomic Abnormalities in Tumours: A Review of Available Methods for Two-Colour SNP Genotyping and Evaluation of Performance'. Cancer Genet. 2013 Apr 24.

Cervantes A, Hoskins P, Vergote I, Eisenhauer E, Ghatage P, Carey M, Katsaros D, Poveda A, Provencher D, Tu D, Stuart G. Final results of OV16, a phase II randomized study of sequential cisplatin-topotecan and carboplatin-paclitaxel versus carboplatin-paclitaxel in first line chemotherapy for adavances epithelial ovarian cancer (EOC). A gynecologic Cancer Intergroup Study of NCIC CTG, EORTC-GCG and GEICO. ASCO Annual Meeting (Oral Abstract Session: Gynecologic Cancer), Chicago, Mai 2013.

Moria H. Belanger, Lena Dolman, Suzanna L. Arcand, Zhen Shen, George Chong, Kathleen Klein Oros, Celia M.T. Greenwood, Anne-Marie Mes-Masson, Diane Provencher, Patricia N. Tonin. Titre: Contribution of Recurrent BRCA1 and BRCA2 mutations to ovarian cancer cases and analysis of genomic anomalies in BRCA1 and BRCA2 tumour specimens in the French Canadian Population of Quebec. Présenté à la Journée de la recherche CRCHUM, 10 mai 2013

Bonomi M, Hirte H, Krzyzanowska M, Cheung W, Macfarlane RJ, Ghatage P, Provencher D, Tsao M, McPherson J, McIntosh L, Dancey J. NCIC CTG Trial IND.2206: A phase II study of sunitinib or temsirolimus in patients with advanced rare cancers. Accepté ASCO Annual Meeting, Chicago, Mai 2013.

Konecny GC, Ray-Coquard I, Haluska P, O'Reilly S, Cottu PH, Elit L, Provencher DM, Beckman MW, Bosserman L, Jacod S, Lindsay MA, Glaspy J, Karlan B, Slamon DJ. A multicenter open label phase II study of the efficacy and safety of AMG 479, a fully human monoclonal antibody against insulin-like growth factor type 1 receptor (IGF1R) as second line therapy in patients with recurrent platinum-sensitive ovarian cancer. ASCO Annual Meeting, Chicago, Mai 2013.

Monk B.J., Poveda A., Vergote I., Raspagliesi F., Fujiwara K., Bae D-S., Del Campo J. M., Ray-Coquard I., Provencher D.M., Kalan B. Y., Lhommé C., Richardson G., Gallardo Rinco D., Coleman R.L., Herzog T. J., Martin C., Brize A., Navale L., Warner D., Oza A., A phase 3, randomized, double-blind trial of weekly paclitaxel plus trebananib or placebo in women with recurrent ovarian cancer: Trinova. ESGO session entitled: Late Breaking News/Highlights. UK, 20 octobre 2013.

Morneau M., Foster W., Lalancette M., Nguyen-Hynh, TV., Renaud MC., Samouëlian V., Letarte N. and the Comité de l'évolution des pratiques en oncologie. Adjuvant treatment for endometrial cancer: A literature review and recommendations from the Comité de l'évolution des pratiques en oncologie (CEPO). Gynecol Oncol. 2013 Oct;131(1):231-40

Comité sur l'immunisation du Québec (CIQ) avec la collaboration de Sauthier Ph. La vaccination des pré-adolescents contre les virus du papillome humain (VPH) au Québec : deux ou trois doses? Mai 2013

Sauthier Ph. « Le Registre des Maladies Trophoblastique en 2012 : un cadeau pour Noël » Journal Gynobilis décembre 2012, volume 13, #4

Funaro D, Krasny M, Lam C, Desy D, Sauthier Ph, Bouffard D. Extrammamary Paget Disease: Epidemiology and Association to Cancer in a Quebec-based Population. Journal of Lower Genital Tract Diseases 2013,17(2):167-174

Sauthier Ph. « Pénurie ou pléthore médicale ? Regards croisés entre le Québec et la Suisse », avril 2013,Journal Gynobilis, volume 14, #1.

Sauthier Ph. Pénurie ou pléthore médicale ? Regards croisés entre le Québec et la Suisse. Journal Forum Gynécologie, Société Suisse de Gynécologie Obstétrique, 28 mai 2013

Fawaz ZS, Barkati M, Beauchemin MC, Sauthier P, Gauthier P, Nguyen TV.Cervical necrosis after chemoradiation for cervical cancer: case series and literature review. Radiat Oncol. 2013 Sep 23;8(1):220.

Mahmud SM, Sangwa-Lugoma G, Nasr SH, Kayembe PK, Tozin RR, Drouin P, Lorincz A, Ferenczy A, Franco EL. Comparison of human papillomavirus testing and cytology for cervical cancer screening in a primary health care setting in the Democratic Republic of the Congo. Gynecol Oncol. 2012 Feb;124(2):286-91

Grandjean Lapierre S, Sauthier P, Mayrand MH, Dufresne S, Petignat P, Provencher D, Drouin P, Gauthier P, Dupuis MJ, Michon B, Ouellet S, Hadjeres R, Ferenczy A, Franco EL, Coutlée F. Human Papillomavirus (HPV) DNA Triage of Women with Atypical Squamous Cells of Undertermined Significance (ASC-US) with Cobas 4800 HPV and Hybrid Capture 2 Tests for Detection of High-Grade Lesions of the Uterine Cervix. J. Clin Microbiol. 2012 Feb 1.

Cormier B, Nezhat F, Sternchos J, Sonoda Y, Leitao MM Jr. Electrocautery-Associated Vascular Injury during Robotic-Assisted Surgery. Obstetrics and Gynecology 2012 Aug;120(2 Pt 2):491-3.

Béatrice Cormier, Philippe Sauthier, Christian Luissier, Geng Zang, Marie-Hélène Mayrand. Determinants of Lymph Node Count in Endometrial Cancer Surgical Staging. International Journal of Gynecological Cancer, octobre 2012;22(8):1361-66.

Grandjean Lapierre S, Sauthier P, Mayrand MH, Dufresne S, Petignat P, Provencher D, Drouin P, Gauthier P, Dupuis MJ, Michon B, Ouellet S, Hadjeres R, Ferenczy A, Franco EL, Coutlée F. Human Papillomavirus (HPV) DNA Triage of Women with Atypical Squamous Cells of Undertermined Significance (ASC-US) with Cobas 4800 HPV and Hybrid Capture 2 Tests for Detection of High-Grade Lesions of the Uterine Cervix. J. Clin Microbiol. 2012 Feb 1.

Perren, T. J., Swart, A.-M., Pfisterer, J., Ledermann, J. A., Pujade-Lauraine, E., Kristensen, G., Carey, M. S., Beale, P., Cervantes, A., Kurzeder, C., du Bois, A., Sehouli, J., Kimmig, R., Stähle, A., Collinson, F., Essapen, S., Gourley, C., Lortholary, A., Selle, F., Mirza, M. R., Leminen, A., Plante, M., Stark, D., Qian, W., Parmar, M. K. B., Oza, A. M., for the ICON7 Investigators*. 2011. A Phase 3 Trial of Bevacizumab in Ovarian Cancer. N. Engl. J. Med. 2011 Dec 29;365(26):2484-96. (*including Provencher, D.) Beth Y. Karlan, Amit M. Oza, Gary E. Richardson, Diane M. Provencher, Vincent L. Hansen, Martin Buck, Setsuko K. Chambers, Prafull Ghatage, Charles H. Pippitt Jr, John V. Brown III, Allan Covens, Raj V. Nagarkar, Margaret Davy, Charles A. Leath III, Hoa Nguyen, Daniel E. Stepan, David M. Weinreich, Marjan Tassoudji, Yu-Nien Sun and Ignace B. Vergote. Randomized, Double-Blind, Placebo-Controlled Phase II Study of AMG 386 Combined With Weekly Paclitaxel in Patients with Recurrent Ovarian Cancer. JCO Feb.01, 2012:362-371. Editorial: Moving Beyond Anti–Vascular Endothelial Growth Factor Therapy in Ovarian Cancer Anil K. Sood, Robert L. Coleman, and Lee M. Ellis. JCO Feb 1, 2012:345-347

Grandjean Lapierre S, Sauthier P, Mayrand MH, Dufresne S, Petignat P, Provencher D, Drouin P, Gauthier P, Dupuis MJ, Michon B, Ouellet S, Hadjeres R, Ferenczy A, Franco EL, Coutlée F. Human Papillomavirus (HPV) DNA Triage of Women with Atypical Squamous Cells of Undertermined Significance (ASC-US) with Cobas 4800 HPV and Hybrid Capture 2 Tests for Detection of High-Grade Lesions of the Uterine Cervix. J. Clin Microbiol. 2012, 50(4):1240.

Wojnarowicz PM, Provencher DM, Mes-Masson AM, Tonin PN. Chromosome 17q25 genes, RHBDF2 and CYGB, in ovarian cancer. Int J Oncol. 40 (6): 1865-1880. Février 2012.

Suzanna L Arcand, Kathleen Klein Oros, Diane Provencher, Anne-Marie Mes-Masson, Celia M.T. Greenwood, Patricia N Tonin. Title: A review of TP53 variants identified in high grade ovarian serous carcinomas and their associated genomic landscapes. Second Annual Canadian Human and Statistical Genetics Meeting, Estérel, Québec, mars 2012

Ashley H. Birch, Diane M. Provencher, Anne-Marie Mes-Masson, and Patricia N. Tonin Comparison of normal reference controls used in transcriptome analyses of high grade serous ovarian tumours. 6th Canadian Conference on Ovarian Cancer Research. May 27 - 29, 2012 – Chateau Laurier, Quebec City, Quebec, Canada. Ovarian cancer: Prevention, detection and treatment of the disease and its recurrence. May 10-11, 2012, Pittsburgh.

Karen Gambaro, Michael C. J. Quinn, Paulina Wojnarowicz, Manon de Ladurantaye, Kim Leclerc Désaulniers, Véronique Barres, Jean-Sébastien Ripeau, Suzanna L. Arcand, Elaine C. Davis, Josée Lavoie, Diane M. Provencher, Anne-Marie Mes-Masson, Mario Chevrette, Patricia N. Tonin Expression of VGLL3 associated with tumour suppressor phenotype in epithelial ovarian cancer. 6th Canadian Conference on Ovarian Cancer Research. May 27 - 29, 2012 – Chateau Laurier, Quebec City, Quebec, Canada

Lena Dolman, Moria H. Belanger, Suzanna L. Arcand Zhen Shen, George Chong, Anne-Marie Mes-Masson,, Diane Provencher, N. Tonin. The contribution of recurrent BRCA2 mutations among French Canadian ovarian cancer cases. 6th Canadian Conference on Ovarian Cancer Research. May 27 - 29, 2012 – Chateau Laurier, Quebec City, Quebec, Canada

Tamal Das, Liliane Meunier, Thomas Gervais, Laurent Barbe, Olivier Guenat, Diane Provencher, Anne-Marie Mes-Masson. Empirical chemosensitivity testing using a microfluidics-based multiplex platform. 6th Canadian Conference on Ovarian Cancer Research. May 27 - 29, 2012 – Chateau Laurier, Quebec City, Quebec, Canada

Guergana Tchakarska, Michael C J Quinn, Sohrab P. Shah, Ali Bashashati, Karey Shumansky, Suzanna L Arcand, Diane Provencher, Patricia N Tonin, David Huntsman, Anne-Marie Mes-Masson. Mutation analysis of cell lines derived from matched primary and recurrent epithelial ovarian cancers using next generation sequencing technology, with a focus on cell cycle related genes. 6th Canadian Conference on Ovarian Cancer Research. May 27 - 29, 2012 – Chateau Laurier, Quebec City, Quebec, Canada

Manon de Ladurantaye, Cécile Lepage, Martin Kobel, Kurosh Rahimi, Jason Madore, Sindy Babinszky, Dimcho Bachvarov, Magdelena Bachvarova, Marie-Claude Beauchamp, Carol E. Cass, Dianne Chadwick, Colleen Crane, Sambasivarao Damaraju, Jennifer Dufour, Walter H. Gotlieb, Steve E. Kalloger, Lise Portelance, Jessica N, McAlpine, Isabelle Matte, Alain Piché, Barbara C. Vanderhyden, Peter H. Watson, David G. Huntsman, Diane Provencher, Anne-Marie Mes-Masson. Report on a quality control exercise performed on specimens from Canadian biobanks participating in the Coeur Specimen Repository. Canadian Conference on Ovarian Cancer Research. May 27 - 29, 2012 – Chateau Laurier, Quebec City, Quebec, Canada

Abd-Rabbo D, Abaji C, Cardin GB, Filali-Mouhim A, Arous C, Portelance L, Escobar E, Cloutier S, Tonin PN, Provencher DM, Mes-Masson AM, Maugard CM. Allelic Transcripts Dosage Effect in Morphologically-Normal Ovarian Cells from Heterozygous Carriers of a BRCA1/2 French Canadian Founder Mutation. Cancer Prev Res (Phila). 2012 May;5(5):765-77

Cécile Le Page, Alexandre Martineau, Patrick K. Bonza, Louis Cyr, Kurosh Rahimi, Nathalie Delvoye, Anne-Marie Mes-Masson, Diane M. Provencher, Jean-Francois Cailhier. BTN3A2/BT3.2 butyrophilin expression by EOC cells favors an immune microenvironment and a better survival of patients. BTN3A2/BT3.2 butyrophilin expression in EOC is associated with patients survival and antitumor response. PlosOne 2012;7(6) June

Gang He, Christina A. Holcroft, Marie-Claude Beauchamp, Amber Yasmen, Alex Ferenczy, Jennifer Kendall-Dupont, Anne-Marie Mes-Masson, Diane Provencher, Walter Gotlieb. Combination of serum biomarkers to differentiate malignat from benign ovarian tumors. J Obstet Gynaecol Can. 2012 Jun;34(6):567-74

Jan Lubinski, Tomasz Huzarski, Tomasz Byrski, Henry T Lynch, Cezary Cybulski, Parviz Ghadirian, Malgorzata Stawicka, William D Foulkes, Ewa Kilar, Charmaine Kim-Sing, Susan Neuhausen, Nadine Tung, Susan Armel, Dawna Gilchrist, Peter Ainsworth, Kevin Sweet, Jacek Gronwald, Andrea Eisen, Bohdan Gorski, Ping Sun, Steven A Narod and the Hereditary Breast Cancer Clinical Study Group (including Diane M Provencher). The Risk of Breast Cancer in Women with a BRCA1 Mutation from North America and Poland. Int J Cancer. 2012 Jul 1;131(1):229-34

Isabelle Letourneau, Michael CJ Quinn, Lu-Lin Wang, LisePortelance, Katia Y Caceres, Louis Cyr, Nathalie Delvoye, Liliane Meunier, Manon de Ladurantaye, Zhen Shen, Suzanna L Arcand, Patricia N Tonin, Diane Provencher and Anne-Marie Mes-Masson. Derivation and characterization of matched cell lines from primary and recurrent serous ovarian cancer. BMC Cancer 2012, Aug.29;12(1):379

Paulina Wojnarowicz, Karen Gambaro, Manon de Ladurantaye, Michael CJ Quinn, Diane Provencher, Anne-Marie Mes-Masson and Patricia N Tonin. Overexpressing the CCl2 chemokine in an epithelial ovarian cancer cell line results in latency of in vivo tumourigencity. Oncogenesis. 2012 Sep 10.

Paulina M Wojnarowicz BSc, Kathleen Klein Oros PhD, Michael CJ Quinn PhD, Suzanna L Arcand MSc, Karen Gambaro PhD, Jason Madore MSc, Ashley H Birch BSc, Manon de Ladurantaye, Kurosh Rahimi, MD, Diane M Provencher MD, Anne-Marie Mes-Masson PhD, Celia MT Greenwood PhD, Patricia N Tonin Ph. The genomic landscape of TP53 and p53 annotated high grade ovarian serous carcinomas from a define founder population associated with patient outcome. PLoS ONE, Septembre 2012, Vol.7, Issue 9.

X.B. Trinh, J. Pauty, J.-Y. Masson, A.-M. Mes-Masson, D.M. Provencher, M. Plante, D. Bachvarov. Title: Differential parpi-responses in BRCA2 mutated ovarian cancer cells and prmiary cell cultures: a pilot study. IGCS 14th Biennal Meeting, 13-16 octobre 2012, Vancouver.

Mes-Masson, Anne-MarieKatia Caceres, Véronique Barres, Patricia Tonin, Diane Provencher, Tamal Das, Liliane Meunier, Olivier Guenat, Thomas Gervais. Biomarkers in epithelial ovarian cancer – or should we go with the flow? SSR's 45th Annual Meeting, 2012

E. Leblanc, C. Lhommé, T. de la Motte Rouge, F. Narducci, V. Samouëlian . « CancéroGuide Ovaire » 2012, Edition Margaux Orange. ISBN : 978-2-914206-37-2

Poilblanc M, Samouëlian V, Querleu D. Bull Cancer. Ovarian preservation during treatment of early stage endometrial cancer. 2012 Jan;99(1):61-8.

Narducci F, Samouelian V, Marchaudon V, Koenig P, Fournier C, Phalippou J, Leblanc E. Vacuum-assisted closure therapy in the management of patients undergoing vulvectomy. Eur J Obstet Gynecol Reprod Biol. 2012 Apr;161(2):199-201.

Nathalie Letarte, William Foster, Lalancette, Thu Van Nguyen-Huynh, Marie-Claude Renaud, Vanessa Samouëlian, Mélanie Morneau. « Traitement néoadjuvant et adjuvant du cancer de l'endomètre. » Comité de l'évolution des pratiques en oncologie (CEPO). Novembre 2012, ISBN 978-2-550-66348-5

Goggin P, Mayrand MH avec la collaboration de Sauthier Ph. Avis du comité sur l'immunisation du Québec et comité scientifique ad hoc VPH. Vaccination contre les VPH au Québec : mise à jour des connaissances et propositions du comité d'experts. 2012

Grandjean Lapierre S, Sauthier Ph, Mayrand MH, Dufresne S, Petignat P, Provencher D, Drouin P, Gauthier Ph, Dupuis MJ, Michon B, Ouellet S, Hadjeres R, Ferenczy A, Franco E, Coutlee F. Human Papillomavirus (HPV) DNA Triage of Women with Atypical Squamous Cells of Undertermined Significance (ASC-US) with Cobas 4800 HPV and Hybrid Capture 2 Tests for Detection of High-Grade Lesions of the Uterine Cervix. Journal of Clinical Microbiology 2012, 50(4) 1240-1244.

Cormier B, Sauthier Ph, Luissier Ch, Zang G, Mayrand MH. Determinants of Lymph Node Count in Endometrial Cancer Surgical Staging. International Journal of Gynecological Cancer 2012;22(8):1361-66.

Lives affected by cancer... 800 women speak. Canadian Cosmetic, Toiletry & Fragrance Association Foundation and the Health Care Advisory Committee: Jennifer Blake, Denny DePetrillo, Pierre Drouin, Margaret I. Fitch, Marilyn J. Hundleby. Published in English & French, 2010. Official launch to media, March 2011.

Simon Dufresne, Philippe Sauthier, Marie-Hélène Mayrand, Patrick Petignat, Diane Provencher, Pierre Drouin, Philippe Gauthier, Marie-Josée Dupuis, Bertrand Michon, Stéphan Ouellet, Rachid Hadjeres, Alex Ferenczy, Eduardo L. Franco and François Coutlée, et al. Human papillomavirus (HPV) DNA triage of women with atypical squamous cells of undetermined significance with amplicor HPV and hybrid capture 2 assays for detection of high-grade lesions of the uterine cervix. Journal of Clinical Microbiology, Jan. 2011, 49 (1) p.48-53

Cormier B, et al. Establishing a sentinel lymph node mapping algorithm for the treatment of early cervical cancer. Gynecol Oncol. 2011 Aug;122 (2):275-280.

Simon Dufresne, Philippe Sauthier, Marie-Hélène Mayrand, Patrick Petignat, Diane Provencher, Pierre Drouin, Philippe Gauthier, Marie-Josée Dupuis, Bertrand Michon, Stéphan Ouellet, Rachid Hadjeres, Alex Ferenczy, Eduardo L. Franco and François Coutlée, et al. Human papillomavirus (HPV) DNA triage of women with atypical squamous cells of undetermined significance with amplicor HPV and hybrid capture 2 assays for detection of high-grade lesions of the uterine cervix. Journal of Clinical Microbiology, Jan. 2011, 49 (1) p.48-53

Simon Dufresne, Philippe Sauthier, Marie-Hélène Mayrand, Patrick Petignat, Diane Provencher, Pierre Drouin, Philippe Gauthier, Marie-Josée Dupuis, Bertrand Michon, Stéphan Ouellet, Rachid Hadjeres, Alex Ferenczy, Eduardo L. Franco and François Coutlée, et al. Human papillomavirus (HPV) DNA triage of women with atypical squamous cells of undetermined significance with amplicor HPV and hybrid capture 2 assays for detection of high-grade lesions of the uterine cervix. Journal of Clinical Microbiology, Jan. 2011, 49 (1) p.48-53

Ignace Vergote, M.D., Ph. D., Claes G. Tropé, M.D., Ph. D., et al. NCIC Clinical Trial Group-a Gynecologic Cancer Intergroup Collaboration, including Diane Provencher. Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer, N. Engl J. Med 2010: 363: 943-53. Simon Dufresne, Philippe Sauthier, Marie-Hélène Mayrand, Patrick Petignat, Diane Provencher, Pierre Drouin, Philippe Gauthier, Marie-Josée Dupuis, Bertrand Michon, Stéphan Ouellet, Rachid Hadjeres, Alex Ferenczy, Eduardo L. Franco and François Coutlée, et al. Human papillomavirus (HPV) DNA triage of women with atypical squamous cells of undetermined significance with amplicor HPV and hybrid capture 2 assays for detection of high-grade lesions of the uterine cervix. Journal of Clinical Microbiology, Jan. 2011, 49 (1) p.48-53

Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO. et al including Provencher DM. International journal of gynecological cancer: official journal of the International Gynecological Cancer Society. 2011 Feb;21(2):289-95.

Gotlieb, W. H., Amant, F., Advani, S., Goswami, C., Hirte, H., Provencher, D., Somani, N., Yamada, S. D., Tamby, J. F., Vergote, I. Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, placebo-controlled study. Lancet Oncol. 2011 Feb;13(2):154-62.

Osborne RJ, Filiaci V, Schink JC, Mannel RS, Alvarez Secord A, Kelley JL, Provencher D, Scott Miller D, Covens AL, Lage JM. Phase III trial of weekly methotrexane or pulsed dactinomycin for low-rish gestional trophoblastic neoplasia : a gynecologic oncology group study. J Clin Oncol. 2011 Mar 1;29(7):825-31. Editorial in J Clin Oncol. 2011 Mar 1;29(7):786-8.

Raymond John Osborne, Ginny Filiaci, Julian Schink, Robert S. Mannel, Angeles Alvarez-Secord, Joseph L. Kelley, Diane Michele Provencher, David Scott Miller, Allan L Covens, Janice M Lage. A Phase III trial of weekly methotrexate or pulsed dactinomycin for low-risk gestational trophoblastic neoplasia: A Gynecologic Oncology Group Study. J Clin Oncol 29: 825-831, March 2011.

Helen J MacKay, Diane Provencher, Mark Heywood, Dongsheng Tu, Elizabeth, A Eisenhauer, Amit M Oza, Ralph Meyer. Phase II/III study of intraperitoneal chemotherapy after neoadjuvant chemotherapy for ovarian cancer: NCIC CTG OV21 (review). Curr. Oncol. 2011 Apr;18(2):84-90.

Gilles Freyer, Anna V. Tinker and on behalf of the Gynecologic Cancer InterGroup (GCIG), including D. Provencher. Clinical Trials and Treatment of the Elderly Diagnosed With Ovarian Cancer. International Journal of Gynecologic Cancer, 2011 May;21(4):771-775.

Philippe O. Gannon, Sanae Medeici, Cécile Le Page, Martin Beaulieu, Diane Provencher, Anne-Marie Mes-Massons, Manuela M. Santos. Impact of hemochromatosis gene (HFE) mutations on epithelial ovarian cancer risk and prognosis. Int J Cancer. 2011 May 1;128(10):2326-34.

Bordeleau L, Lipscombe L, Lubinski J, Ghadirian P, Foulkes WD, Neuhausen S, Ainsworth P, Pollak M, Sun P, Narod SA; Hereditary Breast Cancer Clinical Study Group et al Provencher D. Diabetes and breast cancer among women with BRCA1 and BRCA2 mutations. Cancer. 2011 May 1;117(9):1812-8.

Gavin C.E. Stuart, MD, FRCSC,* Henry Kitchener, MD,Þ Monica Bacon, RN,þ Andreas duBois, MD, PhD,§ Michael Friedlander, MD, PhD,|| Jonathan Ledermann, MD, FRCP,Þ Christian Marth, MD, PhD,¶ Tate Thigpen, MD, PhD,# Edward Trimble, MD,** and on behalf of the participants of the 4th Ovarian Cancer Consensus Conference (OCCC) including Provencher D, 2010 Gynecologic Cancer InterGroup (GCIG) Consensus Statement on Clinical Trials in Ovarian Cancer Report From the Fourth Ovarian Cancer Consensus Conference. Int J Gynecol Cancer. 2011 May;21(4):750-755.

Provencher DM. « De nombreux projets et d'importantes perspectives.... Le donataire, bulletin de la Fondation du CHUM. Avril 2011.

De de Vries M, Agnihotram RV, Koushik A, Provencher D, Gilbert L, Gotlieb W, Ferenczy A, Coutlée F, Franco EL . Environmental factors and progression of cervical precancerous lesions. May 2011.

Friedlander M, Trimble E, Tinker A, Alberts D, Avall-Lundqvist E, Brady M, Harter P, Pignata S, Pujade-Lauraine E, Sehouli J, Vergote I, Beale P, Bekkers R, Calvert P, Copeland L, Glasspool R, Gonzalez-Martin A, Katsaros D, Kim JW, Miller B, Provencher D, Rubinstein L, Atri M, Zeimet A, Bacon M, Kitchener H, Stuart GC; Gynecologic Cancer InterGroup. Clinical trials in recurrent ovarian cancer. Int J Gynecol Cancer. 2011 May;21(4):771-5.

Mark S. Carey, and Carlyn Gotay and on behalf of the Genecolgic Cancer InterGroup (GCIG), including D. Provencher. Patient-Reported Outcomes, Clinical Trials in Ovarian Cancer. International Journal of Gynecologic Cancer, Vol.21, number 4, May 2011:782-7.

Jessica N. McAlpine and Lari B. Wenzel on behalf of the Gynecologic Cancer InterGroup (GCIG), including D. Provencher. Survivor as an Element of Clinical Trials in Ovarian Cancer. International Journal of Gynecologic Cancer, Vol.21, number 4, May 2011:788-92.

Yoffou PH., Edjekouane L., Meunier L, Tremblay A., Provencher DM., Mes-Masson AM., Carmona E.. Subtype Specific Elevated Expression of Hyaluronidase-1 (HYAL-1) in Epithelial Ovarian Cancer. PloS One. 2011;6(6) :e20701. Epub 2011 Jun 10.

Gary E Richardson, Ignace B Vergote, Amit M Oza, Vit L Hansen, Diane Provencher, Prafull Ghatage, Marjan Tassoudji, Daniel E Stepan, David M Weinreich, Beth Y Karlan,et al. AMG 386 plus weekly paclitaxel for the treatment of advanced ovarian cancer: a randomized, double-blind, placebo-controlled phase 2 study. Clinical Oncological Society of Australia, July 27, 2011.

Isabelle J Létourneau, Michael C J Quinn, Lu-Lin Wang, Lise Portelance, Katia Y Caceres, Louis Cyr, Nathalie Delvoye, Liliane Meunier, Suzanna Arcand, Patricia N Tonin, Diane M Provencher, Anne-Marie Mes-Masson Characterization of ovarian cancer cell lines derived from matched pre- and post-chemotherapy samples and determination of their drug resistance status. BMC Cancer, July 2011.

Mona El Khoury, Maude Labelle, Lucie Lalonde, Julie David, Isabelle Trop, Nadine Dumas, Diane Provencher, Is my patient at increased risk of breast cancer? A counseling primer with clinical vignettes. RSNA Abstract 2011

Oza AM, Elit L, Tsao MS, Kamel-Reid S, Biagi J, Provencher DM, Gotlieb WH, Hoskins PJ, Ghatage P, Tonkin KS, Mackay HJ, Mazurka J, Sederias J, Ivy P, Dancey JE, Eisenhauer EA. Phase II Study of Temsirolimus in Women With Recurrent or Metastatic Endometrial Cancer: A Trial of the NCIC Clinical Trials Group. Journal of Clinical Oncology Aug.20; 29(24):3278 -3285,2011

Dr. Thomas J. Herzog, Jan B Vermorken ; Eric Pujade-Lauraine ; Diane M Provencher; Agnieszka Jagiello-Gruszfeld ; Beihua Kong ; Karin Boman ; Youn Choi Park; Trilok Parekh ; Claudia Lebedinsky Correlation between CA-125 serum level and response by recist in a phase III recurrent ovarian cancer study. . Gynecologic Oncology Aug; 122 (2011) 350–355.

S. Cote, S.L. Arcand, R. Royer, S. Nolet, A.-M. Mes-Masson, P.Ghadirian, W.D. Foulkes, M. Tischkowitz, S.A. Narod, D. Provencher, and P.N. Tonin. The BRCA2 c.9004G>A (E2003K) variant is likely pathogenic and recurs in breast and/or ovarian cancer families of French Canadian descent". Breast Cancer Research and Treatment. Sept. 2011.

S.L. Arcand, S. Côté, S. Nolet, P. Ghadiria, W.D. Foulkes, M.D. Tischkowitz, A.-M. Mes-Masson, D. Provencher, P.N. Tonin BRCA2:E3002K, a new recurring mutation in the founder French Canadian population of Quebec. ICHG, 2nd Joint Meeting on Hereditary Breast and Ovarian Cancer, 14-17 sept. 2011, NYU Cancer Institute, New York

Ashley H. Birch, Suzanna L. Arcand, Kathleen Klein Oros, Kourosh Rahimi, A. Kevin Watters, Diane Provencher, Celia M. Greenwood, Anne-Marie Mes-Masson, Patricia N. Tonin, et al. Genome-wide SNP array analyses of benign, low malignant potential and low grade serous epithelial ovarian tumours identify chromosomal anomalies, including a novel fusion gene. 12th International Congress of Human Genetics Montréal, 11-15 octobre 2011.

Kathleen Klein, Suzanna Arcand, Ashley Birch, Diane Provencher, Jeremy Squire, Anne-Marie Mes-Masson, Patricia Tonin, Celia Greenwood, et al. Detecting copy number aberrations in tumours using SNP array technology: A comparison of several available methods. 12th International Congress of Human Genetics Montréal, 11-15 octobre 2011.

Paulina Wojnarowicz, Suzanna Arcand, Kathleen Klein Oros, Diane Provencher, Anne-Marie Mes-Masson, Celia Greewood, Patricia Tonin, et al. Chromosome 17 anomalies inferred by high-density genotyping of benign, borderline and malignant serous ovarian cancer specimens. 12th International Congress of Human Genetics Montréal, 11-15 octobre 2011.

Suzanna L. Arcand, Stephanie Côté, Serge Nolet, Parviz Ghadirian, William Foulkes, Marc Tischkowitz, Anne-Marie Mes-Masson, Diane Provencher, Patricia Tonin, et al. BRCA2:E3002K, a new recurring mutation in the founder French Canadian populationof Quebec. 12th International Congress of Human Genetics Montréal, 11-15 octobre 2011.

Samuel N. Smillie, Karen Gambaro, Diane Provencher, Anne-Marie Mes-Masson, Patricia Tonin, et al. Transcripton Based Bioinformatic Analysis of a Unique Ovarian Cancer Model. 12th International Congress of Human Genetics Montréal, 11-15 octobre 2011

Karen Gambaro, Paulina Wojnarowicz, Manon de Ladurantaye, Kim Leclerc Désaulniers, Véronique Barres, Jean-Sébastien Ripeau, Suzanna Arcand, Josée Lavoie, Diane M. Provencher, Anne-Marie Mes-Masson, Mario Chevrette, Patricia N. Tonin, et al. Genetic and functional evidence of the presence of a tumour suppressor gene in 3p12-cen region in a model of epithelial ovarian cancer. 12th International Congress of Human Genetics Montréal, 11-15 octobre 2011.

Patricia N. Tonin, The Montreal Ovarian Cancer Study Group, Diane Provencher, Anne-Marie Mes-Masson, Celia Greenwood, et al. TP53 and large-scale SNP analyses of high-grade serous ovarian carcinomas from a well-defined population with unique genetic demography. 12th International Congress of Human Genetics,October 11-15, 2011 Montreal.

Amit M. Oza, Vincent Castonguay, Daliah Tsoref, Ivan Padilla, Katherine Karakasis, Helen Mackay, Stephen Welch, Johanne Weberpals, Paul Hoskins, Marie Plante, Diane Provencher, Katia Tonkin, Al Covens, Prafull Ghatge, Jean Gregoire, Hal Hirte, Dianne Miller, Barry Rosen, Jean Maroun, Gavin Stuart. Progression-free Survival in Advanced Ovarian Cancer: A Canadian Review and Expert Panel Perspective. Current Oncology Oct. 18 (2011); Suppl 2:S20-7.

Ashley H. Birch, Suzanna L. Arcand, Kathleen K. Oros, Kurosh Rahimi, A. Kevin Watters, Diane Provencher, Celia M. Greenwood, Anne-Marie Mes-Masson, Patricia N. Tonin. Chromosome 3 Anomalies Investigated by Genome Wide SNP Analysis of Benign, Low Malignant Potential and Low Grade Ovarian Serous Tumours. PLoS ONE Decembre 2011, 6(12): 1-20.

Michel S, Drain A, Closset E, Deruelle P, Ego A, Subtil D, Boodhun R, Boulanger L, Boukerrou M, Bourgain A, Bresson S, Brochot C, Caquant F, Closset E, Collinet P, Cosson M, Coulon C, Coursier J, Goarant L, Coutty N, Couvreux D, Dedet B, Delarue E, Delelis A, Deruelle P, Descamps O, Dufour P, Fline MH, Girard JM, Houfflin-Debarge V, Houpeau JL, Lambaudie E, Lucot JP, Mosser-Depret S, Mubiayi N, Picod G, Pinelle F, Popovic I, Puech F, Rubod C, Sabbah E, Sabban F, Samouelian V, Sicot B, Somme A, Subtil D, Vaast P, Vinatier D. Evaluation of a decision protocol for type of delivery of infants in breech presentation at term. Eur J Obstet Gynecol Reprod Biol. 2011 Oct; 158(2):194-8.

Sauthier Ph. "Le génie génétique", Journal Gynobilis avril 2011, volume 12, #1

Sauthier Ph. "Incendies", Journal Gynobilis juin 2011, volume 12, #2

Sauthier Ph. "Cancer : Journal Gynobilis Cesser le combat et choisir de vivre", décembre 2011, volume 12, #4

Goggin P, Mayrand MH avec la collaboration de Sauthier Ph. Lignes directrices pour le dépistage du cancer du col utérin au Québec. 2011

Dufresne S, Sauthier P, Mayrand MH, Petignat P, Provencher D, Drouin P, Gauthier P, Dupuis MJ, Michon B, Ouellet S, Hadjeres R, Ferenczy A, Franco ELF, Coutlée F. Human Papillomavirus (HPV) DNA Triage of Women with Atypical Squamous Cells of Undetermined Significance with Amplicor HPV and Hybrid Capture 2 Assays for Detection of High-Grade Lesions of the Uterine Cervix. Journal of Clinical Microbiology 2011 Jan; 49:48-53.

Lee CK, Friedlander M, Brown C, Gebski VJ, Georgoulopoulos A, Vergote I, Pignata S, Donadello N, Schmalfeldt B, Delva R, Mirza MR, Sauthier Ph, Pujade-Lauraine E, Lord SJ, Simes RJ. Early Decline in Cancer Antigen 125 as a Surrogate for Progression-Free Survival in Recurrent Ovarian Cancer. J Natl Cancer Inst 2011;103:1–5.

Messaed C, Chebaro W, Di Roberto R, Rittore C, Cheung A, Arseneau J, Schneider A, Chen MF, Bernishke K, Surti U, Hoffner L, Sauthier Ph, Buckett W, Qian JH, Lau NM, Bagga R, Engert JC, Coullin Ph, Touitou I, Slim R, HM Collaborative Group. NLRP7 in the spectrum of reproductive wastage : rare non-synonimous variants confer genetic susceptibility to recurrent reproductive wastage. J Med Genet 2011 :48 :540-548.

Sauthier M, Breguet M, Provencher D, Sauthier Ph. Base de données pour les maladies trophoblastiques. JOGC 2011;

Oonk MH, van Hemel BM, Hollema H, de Hullu JA, Ansink AC, Vergote I, Verheijen RH, Maggioni A, Gaarenstroom KN, Baldwin PJ, van Dorst EB, van der Velden J, Hermans RH, van der Putten HW, Drouin P, Runnebaum IB, Sluiter WJ, van der Zee AG. Size of sentinel-node metastasis and chances of non-sentinel-node involvement and survival in early stage vulvar cancer: results from GROINSS-V, a multicentre observational study. Lancet Oncol. 2010 Jul;11(7):646-52.

Lara Hathout, Philippe Desprès, Thu Van Nguyen, Pierre Drouin, Diane Provencher, Philippe Gauthier, Marjory Jolicoeur, et al. Salvage treatment of pelvic recurrence for uterine cervical cancer. Gynecoly Oncology, October 2010.

Bujold E, (Cormier B) et al. The role of uterine closure in the risk of uterine rupture. Obstet Gynecol 2010;116:43-50.

Van Schalkwyk J, Van Eyk N; Society of Obstetricians and gynaecologists of Canada Infectious Committee (Cormier B) et al. Antibiotic prophylaxis in obstetric procedures. J Obstet Gynaecol Can. 2010 Sep;32(9):878-92

Lara Hathout, Philippe Desprès, Thu Van Nguyen, Pierre Drouin, Diane Provencher, Philippe Gauthier, Marjory Jolicoeur, et al. Salvage treatment of pelvic recurrence for uterine cervical cancer. Gynecoly Oncology, October 2010.

Stéphanie Côté, Serge Nolet, Karyn Latour, Nadine Dumas, Marie-Claire Binet, Magali Breguet, Louis Gaboury, Pavel Hamet, Nicole Larouche, Guylaine Proulx, Diane M. Provencher, Johanne Richard, Christine Wilmart et Christian M. Mauguard. Amélioration du taux de détection du panel de mutations canadiennes-françaises de BRCA1 et BRCA2 au Service de médecine génique. Les 5e assises de génétique humaine et médicale, Strasbourg, France, janvier 2010.

Madore J, Ren F, Filali-Mouhim A, Sanchez L, Kobel M, Tonin PN, et al. including D. Provencher) Characterization of the molecular differences between ovarian endometrioid carcinoma and ovarian serous carcinoma. J Pathol 2010 Feb.;220(3):392-400.

Provencher DM. Un duo de chercheures pour combattre le cancer de l'ovaire! Recherche CRCHUM, vol.2 no.1, mars 2010.

Patricia N Tonin, Michael C.J. Quinn, Karen Gambaro, Diane Provencher, Mario Chevrette, Anne-Marie Mes-Masson. Transcriptome analysis of a genetically modified human ovarian cancer model provedes a framework for biomarker discovery. 13rd Annual Canadian Human Genetics Meeting, St-Sauveur, April 2010.

Paulina Wojnarowicz, Suzanna L Arcand, Diane Provencher, Anne-Marie Mes-Masson, Patricia Tonin. Epithelial ovarian cancer disease states differ in chromosome 17 content and TP53 mutation status. 13rd Annual Canadian Human Genetics Meeting, St-Sauveur, April 2010.

Michael C J Quinn, Suzanna L Arcand, Manon de Ladurantaye, Dan Wilson, Fiona Young, David Englert, Anne-Marie Mes-Masson, Diane Provencher, Patricia Tonin. Trancriptome analysis of 93 genes selected for their biomarker potential in high grade serous ovarian cancers. Terry Fox Research Institute 2nd Annual Scientific Meeting, Vancouver, May 13-15, 2010.

Paulina Wojnarowicz, Suzanna L Arcand, Diane Provencher, Anne-Marie Mes-Masson, Patricia Tonin. Survey of chromosome 17 abnormalities across a spectrum of epithelial ovarian cancer disease states by whole genome SNP analysis. McGill Human Genetics Departmental Research Day, Montreal, May 27 2010.

Patricia N. Tonin, Michael C.J. Quinn, Karen Gambaro, Diane Provencher, Mario Chevrette, Anne-Marie Mes-Masson. Biomarker potential of a novel ovarian cancer cell line model modified by chromosome transfer that exhibits suppression of tumorigenic potential. 5th Canadian Conference on Ovarian Cancer Research, Toronto, May 2010.

Isabelle J Létourneau, Lu-Lin Wang, Louis Cyr, Cécile Le Page, Patricia Tonin, Diane Provencher, Anne-Marie Mes-Masson. Determination of the drug resistance status of nine new cell lines derived from pre and post-chemotherapy samples. 5th Canadian Conference on Ovarian Cancer Research, Toronto, May 2010.

Karen Gambaro, Manon de Ladurantaye, Kim Leclerc Désaulniers, Jean-Sébastien Ripeau, Suzanne Arcand, Josee Lavoie, Diane Provencher, Anne Marie-Mes-Masson, Mario Chevrette, Patricia N. Tonin. Genetic and functional evidence of the presence of a tumor suppressor gene in 3p12-cen region by microcell-mediated chromosome transfer in a model of epithelial ovarian cancer. 5th Canadian Conference on Ovarian Cancer Research, Toronto, May 2010. 5th Canadian Conference on Ovarian Cancer Research, Toronto, May 2010.

Liliane Meunier, Marie-Line Puiffe, Cécile Le Page, Abdelali Filali-Mouhim, Mario Chevrette, Patricia N. Tonin, Diane M. Provencher, Anne-Marie Mes-Masson. Characterization of ovarian ascites on cell migration and gene expression in an In Vitro model. 5th Canadian Conference on Ovarian Cancer Research, Toronto, May 2010.

Patricia N. Tonin, Luca Cavallone, Anne-Marie Mes-Masson, Parvis Ghadirian, Diane Provencher. A breast cancer case under age 36 years is a strong predictive of BRCA1 and BRCA 2 germline mutation in hereditary breast cancer families. RMGA Journées génétiques 2010, Montréal, 3-5 mai 2010.

Trop I, Lalonde L, Mayrand MH, David J, Larouche N, Provencher D. Multimodality breast cancer screening in women with a familial or genetic predisposition. Current Oncology. Curr Oncol. 2010 Jun;17(3) :28-36.

Normandin K, Péant B, Le Page C, De Ladurantaye M, Ouellet V, Tonin PM, et al.(including D. Provencher) Protease inhibitor SERPINA1 expression in epithelial ovarian cancer. Clin Exp Metastasis 2010;27:55-69

Véronique Barrès, Véronique Ouellet, Julie Lafontaine, Patricia N Tonin, Diane M Provencher and Anne-Marie Mes-Massons. An essential role for Ran GTPase in epithelial ovarian cancer cell survival. Molecular Cancer 2010, 9:272.

Wiegand KC, Shah SP, Al-Agha OM, Zhao Y, Tse K, Zeng T, Senz J, McConechy MK, Anglesio MS, Kalloger SE, Yang W, Heravi-Moussavi A, Giuliany R, Chow C, Fee J, Zayed A, Prentice L, Melnyk N, Turashvili G, Delaney AD, Madore J, Yip S, McPherson AW, Ha G, Bell L, Fereday S, Tam A, Galletta L, Tonin PN, Provencher D, Miller D, Jones SJ, Moore RA, Morin GB, Oloumi A, Boyd N, Aparicio SA, Shih IeM, Mes-Masson AM, Bowtell DD, Hirst M, Gilks B, Marra MA, Huntsman DG. ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med. 2010 Oct 14;363(16):1532-43. Epub 2010 Sep 8. --------------------------------------------------Editorial, Michael J. Birrer : The Origin of Ovarian Cancer – Is it Getting Clearer? N Engl J. Med. 2010 363: 16.

Meunier L, Puiffe ML, Le Page C, Filali-Mouhim A, Chevrette M, Tonin PN, Provencher DM, Mes-Masson AM. Effect of ovarian cancer ascites on cell migration and gene expression in an epithelial ovarian cancer in vitro model. Transl Oncol. 2010 Aug 1:3(4):230-8.

Zietarska M, Madore J, Diallo JS, Delvoye N., Saad F, Provencher D, Mes-Massons AM. A novel method of cell embedding for tissue microarrays. Hispathology. 2010 Aug;57(2):323-9.

Provencher DM. « Corps+ Esprit, Examen en 15 points » dossier cancer du sein. Article publié sans « Vita », vol. 130, Octobre 2010.

Hoskins P, Vergote I, Cervantes A, Tu D, Stuart G, Zola P, Poveda A, Provencher D, Katsaros D, Ojeda B, Ghatage P, Grimshaw R, Casado A, Elit L, Mendiola C, Sugimoto A, D'Hondt V, Oza A, Germa JR, Roy M, Brotto L, Chen D, Eisenhauer EA. Advanced ovarian cancer: phase III randomized study of sequential cisplatin-topotecan and carboplatin-paclitaxel vs carboplatin-paclitaxel. J Natl Cancer Inst. 2010 Oct 20;102(20):1547-56.

Provencher DM. « Développements dans le cancer de l'ovaire ». Chumagazine, Novembre-décembre 2010.

Comprehensive BRCA1 and BRCA2 mutation analyses and review of French Canadian families with at least three cases of breast cancer. Cavallon L, Arcand SL, Maugard CM, Nolet S, Gaboury LA, Mes-Massons AM, Ghadirian P, Provencher D, Tonin PN. Fam Cancer.2010 Dec;9(4):507-17

Metcalfe K, Lubinski J, Lynch HT, Ghadirian P, Foulkes WD, Kim-Sing C, Neuhausen S, Tung N, Rosen B, Gronwald J, Ainsworth P, Sweet K, Eisen A, Sun P, Narod SA; Hereditary Breast Cancer Clinical Study Group et al (Provencher D). Family history of cancer and cancer risks in women with BRCA1 or BRCA2 mutations. J Natl Cancer Inst. 2010 Dec 15;102(24):1874-8.

Henry M, Cohen SR, Lee V, Sauthier P, Provencher D, Drouin P, Gauthier P, Gotlieb W, Lau S, Drummond N, Gilbert L, Stanimir G, Sturgeon J, Chasen M, Mitchell J, Huang LN, Ferland MK, Mayo N. The meaning-making intervention (MMI) appears to increase meaning in life in advanced ovarian cancer: a randomized controlled pilot study. Psychooncology 2010 Dec;19(12):1340-7.

V. Samouëlian , MC Baranzelli, A Lesoin. « Uterine papillaryserous carcinoma. », book chapter in « Rare adult tumours management. » Yazid Belkacemi, René-Olivier Mirimanoff, Mahmut Ozsahin, 1st Edition, 2010, Springer Verlag, ISBN: 978-2-287-92245-9.

Are there still contra-indications to laparoscopic treatment of endometrial carcinoma?. Leblanc E, V Samouëlian, Boulanger L, Narducci F. Gynecol Obstet Fertil. 2010 Feb;38(2):119-25. Epub 2010 Jan 27. Review. French.

Sauthier Ph. "J'accuse", Journal Gynobilis mars 2010, volume 11, #1

Sauthier Ph. « Le cancer, la mort, la vie » Série d'article dans La Presse avec Patrick Lagacé, octobre 2010

Sauthier Ph. "Femina Dissectus", Journal Gynobilis septembre 2010, volume 11, #3

Sauthier Ph. "Je déteste Noël", Journal Gynobilis décembre 2010, volume 11, #4

Henry M, Cohen SR, Lee V, Sauthier P, Provencher D, Drouin P, Gauthier P, Gotlieb W, Lau S, Drummond N, Gilbert L, Stanimir G, Sturgeon J, Chasen M, Mitchell J, Huang LN, Ferland MK, Mayo N The Meaning-Making intervention (MMi) appears to increase meaning in life in advanced ovarian cancer: a randomized controlled pilot study. Psychooncology. 2010 Dec;19:1340-7.

Henry M, Cohen Sr, Lee V, Sauthier P, Provencher D, Drouin P, Gauthier P, Gotlieb W, Lau S, Drummond N, Gilbert L, Stanimir G, Sturgeon J, Chasen M, Mayo N. Randomized Control Trial of the Meaning-Making intervention (MMi) for People Newly Diagnosed with Advanced Ovarian Cancer: A Pilot Study. IPOS, Vienna 2009.

Provencher D, Drouin P, Gauthier P, Sauthier P, Nguyen TV, Jolicoeur M, Beauchemin MC, Sagr ER. Stratégies de diagnostic, de traitement et de surveillance dans les cancers gynécologiques du CHUM 2009. www.gynoncoCHUM.ca

Hétu V, Petignat P, Wu Y, Drouin P, Sauthier P, Provencher D, et al. Positive Adnexal or Uterine Serosal Involvement in Stage IIIC Endometrial Cancer is an Adverse Factor for Recurrence. Gynecologic and Obstetric Investigation 2009;67(3):173-7.

The ASTEC/EN.5 writing committee on behalt of the ASTEC/EN,5 Study Group including Drouin, P and Gauthier P. Adjuvant external bam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): pooled trial results, systematic review, and meta-analysis. The Lancet 2009;373(9658):137-46

Williams C, Petignat P, Bélisle A, Drouin P. Primary Abdominal Wall Clear Cell Carcinoma : Case Report and Review of Literature. Anticancer Research 29 (5):1591-1594 (2009).
Maxwell C, (Cormier B) et al. Management Guidelines for Obstetric Patients and Neonates Born to Mothers With Suspected or Probable Severe Acute Respiratory Syndrome (SARS). J Obstet Gynaecol Can. 2009 Apr;30 (4):358-64.

Yudin MH, (Cormier B) et al. Antibiotic therapy in preterm premature rupture of membranes. J Obstet Gynaecol Can. 2009 Sep;31(9):863-7.

Provencher D, Drouin P, Gauthier P, Sauthier P, Nguyen TV, Jolicoeur M, Beauchemin MC, Sagr ER. Stratégies de diagnostic, de traitement et de surveillance dans les cancers gynécologiques du CHUM 2009. www.gynoncoCHUM.ca

Henry M, Cohen Sr, Lee V, Sauthier P, Provencher D, Drouin P, Gauthier P, Gotlieb W, Lau S, Drummond N, Gilbert L, Stanimir G, Sturgeon J, Chasen M, Mayo N. Randomized Control Trial of the Meaning-Making intervention (MMi) for People Newly Diagnosed with Advanced Ovarian Cancer: A Pilot Study. IPOS, Vienna 2009.

Hétu V, Petignat P, Wu Y, Drouin P, Sauthier P, Provencher D, Gauthier P. Positive Adnexal or Uterine Serosal Involvement in Stage IIIC Endometrial Cancer is an Adverse Factor for Recurrence. Gynecologic and Obstetric Investigation 2009;67(3):173-7.

The ASTEC/EN.5 writing committee on behalt of the ASTEC/EN,5 Study Group including Drouin, P and Gauthier P. Adjuvant external bam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): pooled trial results, systematic review, and meta-analysis. The Lancet 2009;373(9658):137-46

Henry M, Cohen Sr, Lee V, Sauthier P, Provencher D, Drouin P, Gauthier P, Gotlieb W, Lau S, Drummond N, Gilbert L, Stanimir G, Sturgeon J, Chasen M, Mayo N. Randomized Control Trial of the Meaning-Making intervention (MMi) for People Newly Diagnosed with Advanced Ovarian Cancer: A Pilot Study. IPOS, Vienna 2009. (présentation orale faite par M Henry)

Birch A, Arcand S, Provencher D, Mes-Masson, Tonin PN. Genome-wide analysis of benign ovarian cystadenomas identifies a region of homozygosity at 3p12. 9th Annual McGill Biomedical Graduate Conference. Montréal, Québec, February 19th, 2009.

Desgagnés J, Barrès V, Lafontaine J, Ouellet V, Tonin P, Provencher D, Mes-Masson AM. Caractérisation de CDC20 et CKS1, régulateurs du cycle cellulaire dans le cancer épithélial de l'ovaire. 19e journée scientifique de l'Institut du cancer de Montréal. 2009.

Barrès V, Lafontaine J, Ouellet V, Tonin PN, Provencher D, Mes-Masson AM. Caractérisation fonctionnelle de la GTPase RAN dans le cancer épithélial de l'ovaire. 19e journée scientifique de l'Institut du cancer de Montréal. 2009.

Nolet S, Latour K, Côté S, Dumas N, Binet MC, Breguet M, Gaboury L, Hamet P, Larouche N, Proulx G, Provencher D, et al. Improvement in the Detection Rate of the BRCA1/BRCA2 French-Canada Mutation Panel at the Service de Médecinie Génique, CHUM. Current Oncology, 2009 vol. 16 no. 5 p93.

Cavallone L, Archand SL, Maugard CM, Mes-Masson AM, Ghadirian P, Provencher D, et al. Breast Cancer at Less Than 36 Years of Age is a Strong Predicator of BRCA1/ 2 Status in French-Canadian Cancer Families. Current Oncology, 2009 vol. 16 no. 5 p 102.

Petru E, Lück HJ, Stuart G, Gaffney D, Millan D, Vergote I; Gynecologic Cancer Intergroup (GCIG)* including Provencher D. Gynecologic Cancer Intergroup (GCIG) proposals for changes of the current FIGO staging system. Eur J. Obstet Gynecol Repord Biol. 2009 April; 143(2):69-74

Manderson EN, Birch AH, Shen Z, Mes-Masson AM, Provencher D, Tonin PN (2008) Molecular genetic analysis of CHL1, CNTN6 and CNTN4 candidate chromosome 3p26pter tumour suppressor genes in ovarian cancer. Int J Gynecol Cancer. 2009 May; 19(4):513-25

Shah SP, Köbel M, Senz J. Morin RD, Clarke BA, Wiegand KC, Leung G, Zayed A, Nehl E, Kalloger SE, Sun M, Giuliany R, Yorida E, Jones S, Varhol R, Swenerton KD, Miller D, Clement PB, Crane D, Madore J. Provencher D et al. Mutation of FOXL2 in Granulosa-Cell tumors of the Ovary. N Engl J Med. 2009 Jun 25:360(26):2719-29.

Power P, Stuart G, Oza A, Provencher D, Bentley JR, Miller WH Jr, Pouliot JF. Efficacy of pegylated liposomal doxorubicin (PLD) plus carboplatin in ovarian cancer patients who recur within six to twelve months: A phase II study. Gynecol Oncol 114(2009) 410-14.

Quinn MC, Wilson DJ, Young F, Dempsey AA, Arcand SN, Circh AH, Wojnarowicz Pn, Mes-Masson AM, Provencher D, Englert D, Tonin PN. The chemiluminescence based Ziplex automated workstation focus array reproduces ovarian cancer Affymetrix GeneChip expression profiles. J Transl Med 2009 Jul 6;7(1):55.

Cody NA, Shen Z, Ripeau JS, Provencher DM, Mes-MassonAM, Chevrette M, Tonin PN. (2009) Characterization of the 3p12.3-pcen region associated with tumor suppression in a novel ovarian cancer cell model genetically modified by chromosome 3 fragment transfer. Molecular Carcinogenesis 2009 Dec;48(12) :1077-92

Hétu V, Petignat P, Wu Y, Drouin P, Sauthier P, Provencher D, Gauthier P. Positive Adnexal or Uterine Serosal Involvement in Stage IIIC Endometrial Cancer is an Adverse Factor for Recurrence. Gynecologic and Obstetric Investigation 2009;67(3):173-7.

Proulx M, Beaulieu MD, Loignon C, Mayrand MH, Maugard CM, Bellavance N, Provencher D. Experiences and Decisions the Motivate Women at Increased Risk of Breast Cancer to Participate in an Experimental Screening Program. J Genet Counsel 2009 18:160-72.

Le Page C, Puiffe M-L, Meunier L, Zietarska M, de Ladurantaye M, Tonin P, Provencher D, Mes-Masson AM. BMP-2 signaling in ovarian cancer and its association with poor prognosis. Journal of Ovarian Research 2009;2(1):4

L. Bresson, F. Narducci, E. Lambaudie, V. Samouëlian , L. Boulanger, E. Leblanc : « Radical hysterectomy for small cervical cancer: role of robot assisted laparoscopy – Congress ECCO 15 - 34TH ESMO » EJC supplements 2009; 7(3): 21.

E Leblanc, D Querleu, F Narducci, V. Samouëlian , L Boulanger, G Ferron. « Laparoscopic Surgeries in Gynaecological Oncology », book chapter in « Testbook of Gynaecological Oncology » Ali Ayhan, Murat Gultekin, Polat Dursun, 1st Edition, 2009, Günes Publishing, ISBN 978-975-277-267-0.

E Leblanc, V. Samouëlian , L Boulanger F Narducci. « Gestion des complications de la vulvectomie radicale (désunion, lymphocèle, infection, lymphoedème) », chapitre de livre dans « Mises à jour en gynécologie et obstétrique et techniques chirurgicales – CNGOF – édition 2009 » Jacques Lansac, Emile Daraï, Dominique Luton, Edition Vigot Maloine – Paris, ISBN : 978-271-140-407-0

Sauthier Ph. " Bien manger pour mieux vivre pendant ses traitements " Conseils diététiques pour la personne en traitement contre le cancer, brochure de la Fondation Québécoise du Cancer, mars 2009

Sauthier Ph. " Ce qu'il faut savoir sur la radiothérapie " Un guide pour la personne en traitement de radiothérapie, brochure de la Fondation Québécoise du Cancer, mai 2009

Sauthier Ph. "L'herbe est-elle plus verte ailleurs ou la neige est-elle plus blanche icitte?", Journal Gynobilis septembre 2009, volume 10 #2

Goggin P, Mayrand MH avec la collaboration de Sauthier Ph. Avis sur l'optimisation du dépistage du cancer du col au Québec. Institut National de Santé Publique du Québec. 2009

Sereda D, Sauthier Ph, Hadjeres R, Funaro D. Aggressive Angiomyxoma of the Vulva: A Case Report and Review of the Literature.J Low Gen Tract Dis 2009;13: 46-50.

Hétu V, Petignat P, Wu Y, Drouin P, Sauthier P, Provencher D, Gauthier P. Positive Adnexal or Uterine Serosal Involvement in Stage IIIC Endometrial Cancer is an Adverse Factor for Recurrence. Gynecologic and Obstetric Investigation 2009;67(3):173-7.

Winnicki M, Gariepy G, Sauthier Ph, Funaro D. Hodgkin Lymphoma Presenting as a Vulvar Mass in a Patient with Crohn Disease: A Case Report and Literature Review. J Low Gen Tract Dis 2009;13: 110-114

Ades. S, Koushik. A, Duarte-Franco. E, Mansour. N, Arseneau. J, Provencher. D, et al. for the Biomarkers of Cervical Cancer Risk Study Team. Selected class I and class II HLA alleles and haplotypes and risk of high-grade cervical intraepithelial neoplasia. International Journal of Cancer 2008;122(12):2820-6.

Birch AH, Quinn MC, Filali-Mouhim A, Provencher DM, Mes-Masson AM, Tonin PN. Transcriptome analysis of serous ovarian cancers identifies differentially expressed chromosome 3 genes. Mol Carcinog 2008;47(1):56 - 65.

Cavallonne L, Arcand SL, Maugard CM, Ghadirian P, Mes-Masson AM, Provencher D, et al. Haplotype analysis of TP53 polymorphisms, Arg72Pro and Ins16, in BRCA1 and BRCA2 mutation carriers of French Canadian descent. BMC Cancer 2008 Apr 10;8:96.

Cody N, Zietarska M, Filali-Mouhim A, Provencher D, Mes-Masson A-M, Tonin P. Influence of monolayer, spheroid, and tumor growth conditions on chromosome 3 gene expression in tumorigenic epithelial ovarian cancer cell lines. BMC Medical Genomics 2008;1(1):34.

Krzakowski M. on behalf DYNEPO Oncology Study Group (including Provencher D). Epoetin delta : efficacy in the treatment of anaemia in cancer patients receiving chemotherapy. Clin Oncol (R Coll Radiol) 2008.

Le Page C, Ouellet V, Quinn MCJ, Tonin PN, Provencher DM, Mes-Masson A-M. BTF4/BTNA3.2 and GCS as Candidate mRNA Prognostic Markers in Epithelial Ovarian Cancer. Cancer Epidemiol Biomarkers Prev 2008 April 1, 2008;17(4):913-20.

Ouellet V, Ling T, Normandin K, Madore J, Lussier C, Provencher D, et al. Immunohistochemical profiling of benign, low malignant potential and low grade serous epithelial ovarian tumors. BMC Cancer 2008;8(1):346.

Ouellet V, Zietarska M, Portelance L, Lafontaine J, Madore J, Provencher D, et al. Characterization of three new serous epithelial ovarian cancer cell lines. BMC Cancer 2008;8(1):152.

Oza AM, Eisenhauer EA, Elit L, Cutz J-C, Sakurada A, Provencher D, et al. Phase II Study of Erlotinib in Recurrent or Metastatic Endometrial Cancer: NCIC IND-148. J Clin Oncol 2008 September 10, 2008;26(26):4319-25.

Petignat P, Usel M, Gauthier P, Popowski Y, Pelte MF, Bouchardy C, et al. Outcome of uterine clear cell carcinomas compared to endometrioid carcinomas and poorly-differentiated endometrioid carcinomas. Eur J Gynaecol Oncol 2008;29(1):57-60.

Arcand SL, Maugard CM, Ghadirian P, Robidoux A, Perret C, Zhang P, Fafard E, Mes-Masson AM, Foulkes WD, Provencher D, Narod SA, Tonin PN: Germline tp53 mutations in brca1 and brca2 mutation-negative french canadian breast cancer families. Breast Cancer Res Treat 2007

Beiner ME, Finch A, Rosen B, Lubinski J, Moller P, Ghadirian P, Lynch HT, Friedman E, Sun P, Narod SA: And hereditary ovairan cancer clinical study group* including Provencher DM. The risk of endometrial cancer in women with brca1 and brca2 mutations. A prospective study. Gynecol Oncol 2007;104:7-10.

Benoit MH, Hudson TJ, Maire G, Squire JA, Arcand SL, Provencher D, Mes-Masson AM, Tonin PN: Global analysis of chromosome x gene expression in primary cultures of normal ovarian surface epithelial cells and epithelial ovarian cancer cell lines. Int J Oncol 2007;30:5-17.

Birch AH, Quinn MC, Filali-Mouhim A, Provencher DM, Mes-Masson AM, Tonin PN: Transcriptome analysis of serous ovarian cancers identifies differentially expressed chromosome 3 genes. Mol Carcinog 2007

Cody NA, Ouellet V, Manderson EN, Quinn MC, Filali-Mouhim A, Tellis P, Zietarska M, Provencher DM, Mes-Masson AM, Chevrette M, Tonin PN: Transfer of chromosome 3 fragments suppresses tumorigenicity of an ovarian cancer cell line monoallelic for chromosome 3p. Oncogene 2007;26:618-632.

Dery M-C, Van Themsche C, Provencher D, Mes-Masson AM, Asselin E: Characterization of en-1078d, a poorly differentiated human endometrial carcinoma cell line : A novel tool to study endometrial invasion in vitro. Reprod Biol Endocrinol 2007;5:38.

Elit L, Zitzelsberger L, Fung-Kee-Fung M, Brouwers M, Graham ID, Browman G, Hoskins P, Lau S, Ghatage P, Society of Gynecologic Oncologists of Canada* including Provencher D: Use of systemic therapy in women with recurrent ovarian cancer--development of a national clinical practice guideline. . Gynecol Oncol 2007;106:181-192.

Fung-Kee-Fung M, Provencher D, Rosen B, Hoskins P, Rambout L, Oliver T, Gotlieb W, Covens A: Intraperitoneal chemotherapy for patients with advanced ovarian cancer: A review of the evidence and standards for the delivery of care. Gynecologic Oncology 2007;105:747-756.

Horsman D, Wilson BJ, Avard D, Meschino WS, Sing CK, Plante M, Eisen A, Howley HE, Simard J: On behalf of the national hereditary cancer task force including Provencher DM. Clinical management recommendations for surveillance and risk-reduction strategies for hereditary breast and ovarian cancer among individuals carrying a deleterious brca1 or brca2 mutation. JOGC 2007:45-60.

Krasner CN, McMeekin DS, Chan S, Braly PS, GRenshaw FG, Kaye S, Provencher D, Campos S, Gore ME: For the et-743-int-ii study group including Drouin P, Gauthier P, Sauthier P. A phase ii study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens. Br J Cancer 2007;Nov 13

McLaughlin JR, Risch HA, Lubinski J, Moller P, Ghadirian P, Lynch H, Karlan B, Fishman D, Rosen B, Neuhausen SL, Offit K, Kauff N, Domchek S, Tung N, Friedman E, Foulkes W, Sun P, Narod SA: And the hereditary ovarian cancer clinical study group* including Provencher DM. Reproductive risk factors for ovarian cancer in carriers of brca1 or brca2 mutations: A case-control study. Lancet Oncol 2007;8:26-34.

Ouellet V, Le Page C, Madore J, Guyot MC, Barres V, Lussier C, Tonin PN, Provencher DM, Mes-Masson AM: An apoptotic molecular network identified by microarray: On the trail to new insights in epithelial ovarian cancer. Cancer 2007;110:297-308.

Petignat P, du Bois A, Bruchim I, Fink D, Provencher DM: Should intraperitoneal chemotherapy be considered as standard first-line treatment in advanced stage ovarian cancer? Critical Reviews in Oncology/Hematology 2007;62:137-147.

Puiffe ML, Le Page C, Filali-Mouhim A, Zietarska M, Ouellet V, Tonin PM, Chevrette M, Provencher D, Mes-Masson AM: Characterization of ovarian cancer ascites on cell invasion, proliferation, spheroid formation, and gene expression in and in vitro model of epithelial ovarian cancer. Neoplasia 2007;9:820-829.

Sauthier P, Petignat P: Diagnostic et prise en charge des neoplasies intraepitheliales vulvaires et des cancers invasifs de la vulve. Gynakol Geburtshilfliche Rundsch 2007;47:88-93.

Schaffer A, Koushik A, Trottier H, Duarte-Franco E, Mansour N, Arseneau J, Provencher D, Gilbert L, Gotlieb W, Ferenczy A, Coutlee F, Pollak MN, Franco EL: Insulin-like growth factor-i and risk of high-grade cervical intraepithelial neoplasia. Cancer Epidemiol Biomarkers Prev 2007;16:716-722.

Tonin PN, Maugard CM, Perret C, Mes-Masson AM, Provencher DM: A review of histopathological subtypes of ovarian cancer in brca-related french canadian cancer families. Fam Cancer 2007

Williams C, Petignat P, Alobaid A, Provencher D, Gauthier P: Chylous ascites after pelvic lymph node dissection for gynecologic cancer. European Journal of Surgical Oncology 2007;33:399-400.

Wright Jr TC, Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D: For the american society for colposcopy and cervical pathology - sponsored consensus conference including provencher dm. 2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests. American Journal of Obstetrics and Gynecology 2007;197:346-355.

Wright Jr TC, Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D: For the american society for colposcopy and cervical pathology - sponsored consensus conference including Provencher DM. 2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests. . J Low Genit Tract Dis 2007;Oct 11:201-222.

Wright TC, Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D: For the 2006 american society for colposcopy and cervical pathologye - sponsored consensus conference including Provencher DM. 2006 consensus guidelines for the management of women with intraepithelial neoplasia or adenocarcinoma in situ. Am J Obstet Gynecol 2007;197:340-345.

Wright TC, Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D: For the 2006 american society for colposcopy and cervical pathologye - sponsored consensus conference including Provencher DM. 2006 consensus guidelines for the management of women with intraepithelial neoplasia or adenocarcinoma in situ. J Low Genit Tract Dis 2007;Oct 11:223-239.

Zietarska M, Maugard CM, Filali-Mouhim A, Alam-Fahmy M, Tonin PN, Provencher DM, Mes-Masson AM: Molecular description of a 3d in vitro model for the study of epithelial ovarian cancer (eoc). Mol Carcinog 2007;46:872-88

Alobaid A, Bruchim I, Verkooijen H, Gauthier P, Petignat P: Adjuvant therapy for patients with stage i papillary serous endometrial cancer. Eur J Surg Oncol 2006;32:358-362.

Casilli F, Tournier I, Sinilnikova OM, Coulet F, Soubrier F, Houdayer C, Hardouin A, Berthet P, Sobol H, Bourdon V, Muller D, Fricker JP, Provencher DM, Capoulade-Metay C, Chompret A, Nogues C, Mazoyer S, Chappuis P, Maillet P, Philippe C, Lortholary A, Gesta P, Bezieau S, Toulas C, Gladieff L, Maugard CM, Dugast C, Delvincourt C, Nguyen TD, Faivre L, Bonadona V, Frebourg T, Lidereau R, Stoppa-Lyonnet D, Tosi M: The contribution of germline rearrangements to the spectrum of brca2 mutations. J Med Genet 2006;43:e49-.

Elit L, Johnston M, Brouwers M, Fung-Kee-Fung M, Browman G, Graham ID, Society of Gynecologic Oncologists of Canada* including Provencher D: Promoting best gynecologic oncology practice : A role for the society of gynecologic oncologists of canada. Current Oncology 2006;13:1-5.

Faught W, Jeffrey J, Bryson P, Dawson L, Helewa M, Kwon J, Lau S, Lotocki R, Provencher D: Management of squamous cell cancer of the vulva. J Obstet Gynaecol Can 2006;28:640-651.

Finch A, Beiner M, Lubinski J, Lynch HT, Moller P, Rosen B, Murphy J, Ghadirian P, Friedman E, Foulkes WD, Kim-Sing C, Wagner T, Tung N, Couch F, Stoppa-Lyonnet D, Ainsworth P, Daly M, Pasini B, Gershoni-Baruch R, Eng C, Olopade OI, McLennan J, Karlan B, Weitzel J, Sun P, Narod SA, for the Hereditary Ovarian Cancer Clinical Study G including Provencher DM: Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a brca1 or brca2 mutation. JAMA 2006;296:185-192.

Ghislain Sangwa-Lugoma, Mahmud S, Nasr SH, Liaras J, Kayembe PK, Tozin RR, Drouin P, Lorincz A, Ferenczy A, Franco EL: Visual inspection as a cervical cancer screening method in a primary health care setting in africa. International Journal of Cancer 2006;119:1389-1395.

Goffin F, Mayrand MH, Gauthier P, Alobaid A, Lussier C, Provencher D, Drouin P, Franco EL, Coutlee F: High-risk human papillomavirus infection of the genital tract of women with a previous history or current high-grade vulvar intraepithelial neoplasia. J Med Virol 2006;78:814-819.

Le Page C, Ouellet V, Madore J, Hudson TJ, Tonin PN, Provencher DM, Mes-Masson AM: From gene profiling to diagnostic markers: Il-18 and fgf-2 complement ca125 as serum-based markers in epithelial ovarian cancer. Int J Cancer 2006;118:1750-1758.

Le Page C, Ouellet V, Madore J, Ren F, Hudson TJ, Tonin PN, Provencher DM, Mes-Masson AM: Gene expression profiling of primary cultures of ovarian epithelial cells identifies novel molecular classifiers of ovarian cancer. Br J Cancer 2006;94:436-445.

McNaught J, Reid RL, Provencher D, Lea R, Jeffrey J, Oza A, Swenerton K: Progesterone-only and non-hormonal contraception in the breast cancer survivor : Joint review and committee opinion of the Society of Obstetricians and Gynaecologists of Canada and the Society of Gynecologic Oncologists of Canada. J Obstet Gynaecol Can 2006;28:616-639.

Oros KK, Ghadirian P, Maugard CM, Perret C, Paredes Y, Mes-Masson AM, Foulkes WD, Provencher D, Tonin PN: Application of brca1 and brca2 mutation carrier prediction models in breast and/or ovarian cancer families of french canadian descent. Clinical Genetics 2006;70:320-329.

Oros KK, Leblanc G, Arcand SL, Shen Z, Perret C, Mes-Masson AM, Foulkes WD, Ghadirian P, Provencher D, Tonin PN: Haplotype analysis suggest common founders in carriers of the recurrent brca2 mutation, 3398delaaaag, in french canadian hereditary breast and/ovarian cancer families. BMC Med Genet 2006;7:23.

Ouellet V, Guyot MC, Le Page C, Filali-Mouhim A, Lussier C, Tonin PN, Provencher DM, Mes-Masson AM: Tissue array analysis of expression microarray candidates identifies markers associated with tumor grade and outcome in serous epithelial ovarian cancer. Int J Cancer 2006;119:599-607.

Ouellet V, Le Page C, Guyot MC, Lussier C, Tonin PN, Provencher DM, Mes-Masson AM: Set complex in serous epithelial ovarian cancer. Int J Cancer 2006;119:2119-2126.

Petignat P, Bouchardy C, Sauthier P: [cervical cancer screening: Current status and perspectives]. Rev Med Suisse 2006;2:1308-1309, 1311-1302.

Petignat P, Jolicoeur M, Alobaid A, Drouin P, Gauthier P, Provencher D, Donath D, Van Nguyen T: Salvage treatment with high-dose-rate brachytherapy for isolated vaginal endometrial cancer recurrence. Gynecol Oncol 2006;101:445-449.

Provencher D: Intraperitoneal chemotherapy for ovarian cancer : A complex strategy but what an exciting avenue ! Bull Cancer 2006;93:959-960.

Sauthier PG, Belanger R, Provencher DM, Gauthier P, Drouin P: Clinical value of image-guided fine needle aspiration of retroperitoneal masses and lymph nodes in gynecologic oncology. Gynecol Oncol 2006;103:75-80.

Thigpen T, Stuart G, du Bois A, et al.: Clinical trials in ovarian carcinoma: requirements for standard approaches and regimens. Ann Oncol 2005;16 Suppl 8:viii13-viii19.

Stuart G, Avall-Lundqvist E, du Bois A, et al.: 3rd International Ovarian Cancer Consensus Conference: outstanding issues for future consideration. Ann Oncol 2005;16 Suppl 8:viii36-viii38.

Presneau N, Shen Z, Provencher D, et al.: Identification of novel variant, 1484delG in the 3'UTR of H3F3B, a member of the histone 3B replacement family, in ovarian tumors. Int J Oncol 2005;26:1621-1627.

Presneau N, Dewar K, Forgetta V, et al.: Loss of heterozygosity and transcriptome analyses of a 1.2 Mb candidate ovarian cancer tumor suppressor locus region at 17q25.1-q25.2. Mol Carcinog 2005;43:141-154.

Petignat P, Hankins C, Walmsley S, et al.: Self-sampling is associated with increased detection of human papillomavirus DNA in the genital tract of HIV-seropositive women. Clin Infect Dis 2005;41:527-534.

Ouellet V, Provencher DM, Maugard CM, et al.: Discrimination between serous low malignant potential and invasive epithelial ovarian tumors using molecular profiling. Oncogene 2005;24:4672-4687.

Millaire M, Alobaid A, Gariepy G, Gauthier P: Metastatic adenocarcinoma of the cervix: a case report. J Obstet Gynaecol Can 2005;27:1113-1116.

Le LH, Swenerton KD, Elit L, et al.: Phase II multicenter open-label study of carboplatin and pegylated liposomal doxorubicin in uterine and cervical malignancies. Int J Gynecol Cancer 2005;15:799-806.

Gagne JP, Gagne P, Hunter JM, et al.: Proteome profiling of human epithelial ovarian cancer cell line TOV-112D. Mol Cell Biochem 2005;275:25-55.

East N, Alobaid A, Goffin F, et al.: Granulosa cell tumour: a recurrence 40 years after initial diagnosis. J Obstet Gynaecol Can 2005;27:363-364.

du Bois A, Quinn M, Thigpen T, et al.: 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). Ann Oncol 2005;16 Suppl 8:viii7-viii12.

Arcand SL, Provencher D, Mes-Masson AM, Tonin PN: OGG1 Cys326 variant, allelic imbalance of chromosome band 3p25.3 and TP53 mutations in ovarian cancer. Int J Oncol 2005;27:1315-1320.

Alobaid A, Goffin F, Lussier C, Drouin P: Aggressive angiomyxoma of the vulva or perineum: report of three patients. J Obstet Gynaecol Can 2005;27:1023-1026.

Samouelian V, Maugard CM, Jolicoeur M, et al.: Chemosensitivity and radiosensitivity profiles of four new human epithelial ovarian cancer cell lines exhibiting genetic alterations in BRCA2,TGFbeta-RII, KRAS2, TP53 and/or CDNK2A. Cancer Chemother Pharmacol 2004;54:497-504.

Oros KK, Ghadirian P, Greenwood CM, et al.: Significant proportion of breast and/or ovarian cancer families of French Canadian descent harbor 1 of 5 BRCA1 and BRCA2 mutations. Int J Cancer 2004;112:411-419.

Migneault B, Girard F, Albert C, et al.: The effect of music on the neurohormonal stress response to surgery under general anesthesia. Anesth Analg 2004;98:527-532, table of contents.

Lea R, Bannister E, Case A, et al.: Use of hormonal replacement therapy after treatment of breast cancer. J Obstet Gynaecol Can 2004;26:49-60; quiz 62-44.

Le Page C, Provencher D, Maugard CM, et al.: Signature of a silent killer: expression profiling in epithelial ovarian cancer. Expert Rev Mol Diagn 2004;4:157-167.

Elit L, Trim K, Mand-Bains IH, et al.: Job satisfaction, stress, and burnout among Canadian gynecologic oncologists. Gynecol Oncol 2004;94:134-139.

Arcand SL, Mes-Masson AM, Provencher D, et al.: Gene expression microarray analysis and genome databases facilitate the characterization of a chromosome 22 derived homogeneously staining region. Mol Carcinog 2004;41:17-38.

Tran-Thanh D, Provencher D, Koushik A, et al.: Herpes simplex virus type II is not a cofactor to human papillomavirus in cancer of the uterine cervix. Am J Obstet Gynecol 2003;188:129-134.

Presneau N, Mes-Masson AM, Ge B, et al.: Patterns of expression of chromosome 17 genes in primary cultures of normal ovarian surface epithelia and epithelial ovarian cancer cell lines. Oncogene 2003;22:1568-1579.

Trudeau M, Stuart G, Hirte H, et al.: A phase II trial of JM-216 in cervical cancer: an NCIC CTG study. Gynecol Oncol 2002;84:327-331.

Tran-Thanh D, Koushik A, Provencher D, et al.: Detection of human herpes virus type 6 DNA in precancerous lesions of the uterine cervix. J Med Virol 2002;68:606-610.

Pearcey R, Brundage M, Drouin P, et al.: Phase III trial comparing radical radiotherapy with and without cisplatin chemotherapy in patients with advanced squamous cell cancer of the cervix. J Clin Oncol 2002;20:966-972.

Narod SA, Dube MP, Klijn J, et al.: Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst 2002;94:1773-1779.

Manderson EN, Presneau N, Provencher D, et al.: Comparative analysis of loss of heterozygosity of specific chromosome 3, 13, 17, and X loci and TP53 mutations in human epithelial ovarian cancer. Mol Carcinog 2002;34:78-90.

Manderson EN, Mes-Masson AM, Novak J, et al.: Expression profiles of 290 ESTs mapped to chromosome 3 in human epithelial ovarian cancer cell lines using DNA expression oligonucleotide microarrays. Genome Res 2002;12:112-121.

Helewa M, Levesque P, Provencher D, et al.: Breast cancer, pregnancy, and breastfeeding. J Obstet Gynaecol Can 2002;24:164-180; quiz 181-164.

Tonin PN, Hudson TJ, Rodier F, et al.: Microarray analysis of gene expression mirrors the biology of an ovarian cancer model. Oncogene 2001;20:6617-6626.

Thompson D, Easton D: Variation in cancer risks, by mutation position, in BRCA2 mutation carriers. Am J Hum Genet 2001;68:410-419.

Narod SA, Sun P, Ghadirian P, et al.: Tubal ligation and risk of ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study. Lancet 2001;357:1467-1470.

Manning AP, Abelovich D, Ghadirian P, et al.: Haplotype analysis of BRCA2 8765delAG mutation carriers in French Canadian and Yemenite Jewish hereditary breast cancer families. Hum Hered 2001;52:116-120.

Wang J, Mes-Masson AM, Tonin PN, et al.: Trisomy of chromosome 10 in two cases of ovarian carcinoma. Cancer Genet Cytogenet 2000;118:65-68.

Provencher DM, Lounis H, Champoux L, et al.: Characterization of four novel epithelial ovarian cancer cell lines. In Vitro Cell Dev Biol Anim 2000;36:357-361.

Narod SA, Brunet JS, Ghadirian P, et al.: Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group. Lancet 2000;356:1876-1881.

Manderson EN, Mes-Masson AM, Provencher D, Tonin PN: Mutations in a 10-bp polyadenine repeat of transforming growth factor beta-receptor type II gene is an infrequent event in human epithelial ovarian cancer. Clin Genet 2000;57:151-153.

Dion F, Mes-Masson AM, Seymour RJ, et al.: Allelotyping defines minimal imbalance at chromosomal region 17q25 in non-serous epithelial ovarian cancers. Oncogene 2000;19:1466-1472.

Tonin PM, Mes-Masson AM, Narod SA, et al.: Founder BRCA1 and BRCA2 mutations in French Canadian ovarian cancer cases unselected for family history. Clin Genet 1999;55:318-324.

Manning AP, Mes-Masson AM, Seymour RJ, et al.: Expression of FHIT in primary cultures of human epithelial ovarian tumors and malignant ovarian ascites. Mol Carcinog 1999;24:218-225.

Dubuc-Lissoir J, S L, Brunet JS, et al.: Laparoscopic Radical Hysterectomy versus Abdominal Radical Hysterectomy : A non-randomized study. Journal SOGC 1999;21:943-950.

D. E, DM) BCLCiP: Cancer Risks in BRCA2 Mutations Carriers. J Natl Cancer Inst 1999;91:1310-1316.

Breast Cancer Linkage Consortium T: Cancer Risks in BRCA2 Mutation Carriers. J Natl Cancer Inst 1999;91:1310-1316.

Tonin PN, Mes-Masson AM, Futreal PA, et al.: Founder BRCA1 and BRCA2 mutations in French Canadian breast and ovarian cancer families. Am J Hum Genet 1998;63:1341-1351.

Soulez G, Oliva VL, Therasse E, Provencher D: Embolization of a large-neck aneurysm of the internal iliac artery with interlocking detachable coils: case report. Can Assoc Radiol J 1998;49:39-41.

Narod SA, Risch H, Moslehi R, et al.: Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study Group. N Engl J Med 1998;339:424-428.

Lounis H, Mes-Masson AM, Dion F, et al.: Mapping of chromosome 3p deletions in human epithelial ovarian tumors. Oncogene 1998;17:2359-2365.

Godard B, Foulkes WD, Provencher D, et al.: Risk factors for familial and sporadic ovarian cancer among French Canadians: a case-control study. Am J Obstet Gynecol 1998;179:403-410.

Provencher DM, Lounis H, Fink D, et al.: Discordance in p53 mutations when comparing ascites and solid tumors from patients with serous ovarian cancer. Tumour Biol 1997;18:167-174.

Coutlee F, Mayrand MH, Provencher D, Franco E: The future of HPV testing in clinical laboratories and applied virology research. Clin Diagn Virol 1997;8:123-141.

Coutlee F, Provencher D, Gauthier J: Is there a clinical utility for HPV detection tests for screening preinvasive and invasive diseases of the uterine cervix ? Germs & Ideas 1996;2:40-44.

Trottier AM, Provencher D, Mes-Masson AM, et al.: Absence of human papillomavirus sequences in ovarian pathologies. J Clin Microbiol 1995;33:1011-1013.

Pomel C, Provencher D, Dauplat J, et al.: Laparoscopic staging of early ovarian cancer. Gynecol Oncol 1995;58:301-306.

Coutlee F, Provencher D, Voyer H: Detection of human papillomavirus DNA in cervical lavage specimens by a nonisotopic consensus PCR assay. J Clin Microbiol 1995;33:1973-1978.

Vial Y, Sauthier P, Maillard-Brignon C, Bossart H: [Complications from chorionic villus sampling and amniocentesis]. J Gynecol Obstet Biol Reprod (Paris) 1994;23:476-480.

Spuhler SC, Sauthier PG, Chardonnens EG, De Grandi P: A new vaginal extractor for laparoscopic surgery. J Am Assoc Gynecol Laparosc 1994;1:401-404.

Spuhler S, Pasche N, Sauthier P, et al.: [Value of penis endoscopy in sexual partners of women with condylomatous or dysplastic lesions]. J Gynecol Obstet Biol Reprod (Paris) 1994;23:660-664.

Sauthier P, Hohlfeld P, Mosimann F, Bossart H: [Liver transplantation and pregnancy: 1994 perspectives]. Arch Gynecol Obstet 1994;255 Suppl 2:S259-271.

Lounis H, Provencher D, Godbout C, et al.: Primary cultures of normal and tumoral human ovarian epithelium: a powerful tool for basic molecular studies. Exp Cell Res 1994;215:303-309.

Spuhler S, Sauthier P, Chardonnens E, De Grandi P: [C.C.L. vaginal extractor for celioscopic surgery]. Arch Gynecol Obstet 1993;253 Suppl:S80-82.

Spuhler S, Sauthier P: [Current indications for colposcopic examination]. J Gynecol Obstet Biol Reprod (Paris) 1993;22:722-728.

Spuhler S, Chardonnens E, Sauthier P, de Grandi P: [The C.C.L. culdotomy extractor for laparoscopic surgery]. J Gynecol Obstet Biol Reprod (Paris) 1993;22:111.

Sauthier P, Spuhler S, De Grandi P: [Problems associated with extraction of tumors in surgical celioscopy]. Arch Gynecol Obstet 1993;253 Suppl:S69-79.

Provencher DM, Finstad CL, Saigo PE, et al.: Comparison of antigen expression on fresh and cultured ascites cells and on solid tumors of patients with epithelial ovarian cancer. Gynecol Oncol 1993;50:78-83.

Chardonnens E, Spuhler S, Sauthier P, De Grandi P: [Patient preparation and technical infrastructure in celioscopy]. Arch Gynecol Obstet 1993;253 Suppl:S61-68.

Swenerton K, Jeffrey J, Stuart G, et al.: Cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in advanced ovarian cancer: a randomized phase III study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1992;10:718-726.

Rubin SC, Finstad CL, Hoskins WJ, et al.: Analysis of antigen expression at multiple tumor sites in epithelial ovarian cancer. Am J Obstet Gynecol 1991;164:558-563.

Rubin SC, Finstad CL, Hoskins WJ, et al.: Expression of P-glycoprotein in epithelial ovarian cancer: evaluation as a marker of multidrug resistance. Am J Obstet Gynecol 1990;163:69-73.

Finstad CL, Saigo PE, Rubin SC, et al.: Immunohistochemical localization of P-glycoprotein in adult human ovary and female genital tract of patients with benign gynecological conditions. J Histochem Cytochem 1990;38:1677-1681.

Audet-Lapointe P, Body G, Vauclair R, et al.: Vaginal intraepithelial neoplasia. Gynecol Oncol 1990;36:232-239.

Abu-Hamad A, Provencher D, Ganjei P, Penalver M: Lymphangioma circumscriptum of the vulva: case report and review of the literature. Obstet Gynecol 1989;73:496-499.

Provencher D, Valme B, Averette HE, et al.: HIV status and positive Papanicolaou screening: identification of a high-risk population. Gynecol Oncol 1988;31:184-190.

Grimard L, Genest P, Girard A, et al.: Prognostic significance of endometrial extension in carcinoma of the cervix. Gynecol Oncol 1988;31:301-309.

Ayoub J, Audet-Lapointe P, Methot Y, et al.: Efficacy of sequential cyclical hormonal therapy in endometrial cancer and its correlation with steroid hormone receptor status. Gynecol Oncol 1988;31:327-337.

Genest P, Drouin P, Girard A, Gerig L: Stage III carcinoma of the endometrium: a review of 41 cases. Gynecol Oncol 1987;26:77-86.

Genest P, Drouin P, Gerig L, et al.: Prognostic factors in early carcinoma of the endometrium. Am J Clin Oncol 1987;10:71-77.

Kane C, Drouin P: Obstructive uropathy associated with endometriosis. Am J Obstet Gynecol 1985;151:207-211.

Gauthier P, Gore I, Shingleton HM, et al.: Identification of histopathologic risk groups in stage IB squamous cell carcinoma of the cervix. Obstet Gynecol 1985;66:569-574.

Muram D, Drouin P: Ovarian remnant syndrome. Can Med Assoc J 1982;127:399-400.

Muram D, Curry RH, Drouin P: Cytologic follow-up of patients with invasive cervical carcinoma treated by radiotherapy. Am J Obstet Gynecol 1982;142:350-354.

Drouin P, Nasah BT, Nkounawa F: The value of the Partogramme in the management of labor. Obstet Gynecol 1979;53:741-745.